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Free radicals, such as superoxide, hydroxy], nitric oxide and other reactive 
oxygen species, like hydrogen peroxide, are formed in vivo. Though nitric oxide, a 
multi-faceted bioregulatory agent produced by many types of cells, is known to play a 
critical role in both regulatory processes and cell defense, yet it also participates in 
collateral reactions, leading to DNA damage and cell death in both nitric oxide 
generating and neighboring cells. 
Though many human genetic disease and cancer are thought to arise from 
deamination of DNA, yet spontaneous (hydrolytic) deamination is extremely 
unfavorable energetically. Certain toxic agents may catalyze this reaction and increase 
the incidence of the genetic disorders. One candidate is nitric oxide, a cigarette 
constituent and environmental pollutant, produced in numerous cell types in amounts 
that can total to 200 millimoles per day per person. This bioregulatory molecule can 
accelerate base deamination, DNA strand breaks, DNA-protein cross-linking and 
cause deamination-induced genetic changes in the living cells along with apoptosis or 
cells death. 
Nitric oxide is an important mediator of the inflammatory response. It is a 
strong proinflammatory substance that may increase vascular permeability in 
inflamed tissues. There is an extensive suggestive evidence that nitric oxide can 
participate as mediator of tissue damage in autoimmune disease. Elevated nitric oxide 
biosynthesis has been associated with chronic inflammatory autoimmune diseases 
including rheumatoid arthritis, inflammatory bowel diseases, glomerulonephritis, 
vasculitis, multiple sclerosis and systemic lupus erythematosus. 
Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease of 
unknown etiology characterized by various immunologic disorders, including 
production of autoantibodies, formation of immune complexes, decreased serum 
complement levels, and lymphocytopenia. The complex and non-organ specific nature 
of SLE has made it difficult of researchers to unravel the genetic defects and 
pathogenic mechanisms underlying this disease. One of the hallmarks of this disease 
both in humans and mice, is the loss of tolerance to nuclear antigens. The dominant 
presence of antibodies against the exposed conformational epitopes on chromatin 
strongly suggests that the pathogenic immune response in lupus is driven by 
chromatin. The demonstration of T cells specific for chromatin components that can 
drive the antinuclear antibody producing B cells tolerance to both murine and human 
lupus further illustrates how loss of B cell and T cell tolerance to chromatin 
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constitutes a central feature of lupus. Although antibodies that react with B 
conformations of DNA are found in sera of patients with SLE, B-DNA per se is a 
poor immunogen. On the other hand, various other conformations like right handed 
A-form and left handed Z-form are immunogenic. Also DNA modified with ROS, 
certain chemicals, in conjunction with the female sex hormone estradiol have been 
found to result in the production of autoantibodies. It has been reported that ROS 
modification of dsDNA results in an increased binding of anti-DNA antibodies from 
SLE sera. 
Nitric oxide is known to cause cell death via apoptosis and serum nitrite levels 
are also reported to be elevated in SLE patients as well. Further, in SLE patients 
increased apoptosis of circulating lymphocytes has been reported. This increased rate 
of apoptosis could lead to an overflow of the apoptotic cell material and thus increase 
nuclear components both normal and modified e.g. dsDNA, nucleosomes or histone in 
serum of these patients. In addition, dysregulated apopotosis and/or phagocytosis may 
trigger and provide survival signals for autoreactive B ceils. 
In the present study, chromatin was isolated from goat liver and modified by 
nitric oxide radical, generated by reduction of sodium nitrite with sodium dithionite. 
The nitric oxide induced modifications in chromatin were analyzed by UV 
spectroscopic, fluorescence, CD and thermal denaturation studies. NO-chromatin 
showed hyperchromicity at 260 nm as compared to native chromatin, reflecting the 
presence of strand breaks and alterations in the structure of chromatin. While 
fluorescence studies showed formation of single strand breaks in DNA and exposure 
of protein chromophoric groups in chromatin. A net decrease of 9 °C in Tm value of 
NO-chromatin as compared to native chromatin at 260 nm was observed while Tm 
value of NO-chromatin was found to be high as compared to native chromatin at 
280 nm. This indicates the formation of single strand breaks in DNA and protein-
protein/protein-DNA adduct or cross-linking due to nitric oxide modification. The 
single strand breaks induced in the modified chromatin upon nitric oxide exposure 
was further ascertained by nuclease S1 sensitivity assay. DNA base modifications in 
modified chromatin were analyzed by DEAE Sephadex A-25 column 
chromatography. Guanine was maximally modified followed by cytosine. 
Native chromatin and NO-chromatin were used to induce antibodies in rabbits 
and were found to be immunogenic inducing high titre antibodies. The modified 
chromatin was highly immunogenic as compared to native chromatin. The repertoire 
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of specificities of induced antibodies was evaluated by direct binding and competition 
ELISA. The immunogen showed a high degree of specificity for the induced 
antibodies. The induced antibodies exhibited polyspecificity, a property commonly 
associated with SLE autoantibodies. Anti-NO-chromatin antibodies recognized 
human blood protein, modified tyrosine polymers, nucleosomes and histone. 
A group of SLE sera was investigated for the evaluation of anti-DNA 
autoantibody titre. SLE IgGs isolated from sera often patients shoving high titre anti-
DNA autoantibodies were analyzed for their specificity towards native calf thymus 
DNA, native chromatin and NO-chromatin by inhibition ELISA. The binding 
specificity of SLE IgGs with NO modified and native chromatin was further analyzed 
by gel retardation assay. Direct binding ELISA results show preferential binding of 
SLE autoantibodies to NO-chromatin in comparison to native chromatin and calf 
thymus DNA. Inhibition ELISA reiterates the direct binding results. Gel retardation 
assay further substantiated the binding of native and modified chromatin with SLE 
autoantibodies. The antigen binding characteristics of SLE IgGs obtained from 
different patients were remarkably similar, including their binding to native and NO-
chromatin. The result suggests that the nitric oxide modification of chromatin causes 
perturbations resulting in the generation of neo-epitopes, thus making it a potential 
immunogen. 
In conclusion, the nitric oxide radical causes extensive damage to chromatin 
and renders it immunogenic. The antibodies against modified chromatin are 
polyspecific in nature, resembling the antigen binding characteristics of SLE 
autoantibodies. The possibility of nitric oxide modified chromatin in the production of 
SLE autoantibodies has been suggested. 
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Free radicals, such as superoxide, hydroxyl, nitric oxide and other reactive 
oxygen species, like hydrogen peroxide, are formed in vivo. Though nitric oxide, a 
multi-faceted bioregulatory agent produced by many types of cells, is known to play a 
critical role in both regulatory processes and cell defense, yet it also participates in 
collateral reactions, leading to DNA damage and cell death in both nitric oxide 
generating and neighboring cells. 
Though many human genetic disease and cancer are thought to arise from 
deamination of DNA, yet spontaneous (hydrolytic) deamination is extremely 
unfavorable energetically. Certain toxic agents may catalyze this reaction and increase 
the incidence of the genetic disorders. One candidate is nitric oxide, a cigarette 
constituent and environmental pollutant, produced in numerous cell types in amounts 
that can total to 200 millimoles per day per person. This bioregulatory molecule can 
accelerate base deamination, DNA strand breaks, DNA-protein cross-linking and 
cause deamination-induced genetic changes in the living cells along with apoptosis or 
cells death. 
Nitric oxide is an important mediator of the inflammatory response. It is a 
strong proinflammatory substance that may increase vascular permeability in 
inflamed tissues. There is an extensive suggestive evidence that nitric oxide can 
participate as mediator of tissue damage in autoimmune disease. Elevated nitric oxide 
biosynthesis has been associated with chronic inflammatory autoimmune diseases 
including rheumatoid arthritis, inflammatory bowel diseases, glomerulonephritis, 
vasculitis, multiple sclerosis and systemic lupus erythematosus. 
Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease of 
unknown etiology characterized by various immunologic disorders, including 
production of autoantibodies, formation of immune complexes, decreased serum 
complement levels, and lymphocytopenia. The complex and non-organ specific nature 
of SLE has made it difficult of researchers to unravel the genetic defects and 
pathogenic mechanisms underlying this disease. One of the hallmarks of this disease 
both in humans and mice, is the loss of tolerance to nuclear antigens. The dominant 
presence of antibodies against the exposed conformational epitopes on chromatin 
strongly suggests that the pathogenic immune response in lupus is driven by 
chromatin. The demonstration of T cells specific for chromatin components that can 
drive the antinuclear antibody producing B cells tolerance to both murine and human 
lupus further illustrates how loss of B cell and T cell tolerance to chromatin 
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constitutes a central feature of lupus. Although antibodies that react with B 
conformations of DNA are found in sera of patients with SLE, B-DNA per se is a 
poor immunogen. On the other hand, various other conformations like right handed 
A-form and left handed Z-form are immunogenic. Also DNA modified with ROS, 
certain chemicals, in conjunction with the female sex hormone estradiol have been 
found to result in the production of autoantibodies. It has been reported that ROS 
modification of dsDNA results in an increased binding of anti-DNA antibodies from 
SLE sera. 
Nitric oxide is known to cause cell death via apoptosis and serum nitrite levels 
are also reported to be elevated in SLE patients as well. Further, in SLE patients 
increased apoptosis of circulating lymphocytes has been reported. This increased rate 
of apoptosis could lead to an overflow of the apoptotic cell material and thus increase 
nuclear components both normal and modified e.g. dsDNA, nucleosomes or histone in 
serum of these patients. In addition, dysregulated apopotosis and/or phagocytosis may 
trigger and provide survival signals for autoreactive B cells. 
In the present study, chromatin was isolated from goat liver and modified by 
nitric oxide radical, generated by reduction of sodium nitrite with sodium dithionite. 
The nitric oxide induced modifications in chromatin were analyzed by UV 
spectroscopic, fluorescence, CD and thermal denaturation studies. NO-chromatin 
showed hyperchromicity at 260 nm as compared to native chromatin, reflecting the 
presence of strand breaks and alterations in the structure of chromatin. While 
fluorescence studies showed formation of single strand breaks in DNA and exposure 
of protein chromophoric groups in chromatin. A net decrease of 9 °C in Tm value of 
NO-chromatin as compared to native chromatin at 260 nm was observed while Tm 
value of NO-chromatin was found to be high as compared to native chromatin at 
280 nm. This indicates the formation of single strand breaks in DNA and protein-
protein/protein-DNA adduct or cross-linking due to nitric oxide modification. The 
single strand breaks induced in the modified chromatin upon nitric oxide exposure 
was further ascertained by nuclease S1 sensitivity assay. DNA base modifications in 
modified chromatin were analyzed by DEAE Sephadex A-25 column 
chromatography. Guanine was maximally modified followed by cytosine. 
Native chromatin and NO-chromatin were used to induce antibodies in rabbits 
and were found to be immunogenic inducing high titre antibodies. The modified 
chromatin was highly immunogenic as compared to native chromatin. The repertoire 
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of specificities of induced antibodies was evaluated by direct binding and competition 
ELISA. The immunogen showed a high degree of specificity for the induced 
antibodies. The induced antibodies exhibited polyspecificity, a property commonly 
associated with SLE autoantibodies. Anti-NO-chromatin antibodies recognized 
human blood protein, modified tyrosine polymers, nucleosomes and histone. 
A group of SLE sera was investigated for the evaluation of anti-DNA 
autoantibody titre. SLE IgGs isolated from sera often patients showing high titre anti-
DNA autoantibodies were analyzed for their specificity towards native calf thymus 
DNA, native chromatin and NO-chromatin by inhibition ELISA. The binding 
specificity of SLE IgGs with NO-modified and native chromatin was further analyzed 
by gel retardation assay. Direct binding ELISA results show preferential binding of 
SLE autoantibodies to NO-chromatin in comparison to native chromatin and calf 
thymus DNA. Inhibition ELISA reiterates the direct binding results. Gel retardation 
assay further substantiated the binding of native and modified chromatin with SLE 
autoantibodies. The antigen binding characteristics of SLE IgGs obtained from 
different patients were remarkably similar, including their binding to native and NO-
chromatin. The result suggests that the nitric oxide modification of chromatin causes 
perturbations resulting in the generation of neo-epitopes, thus making it a potential 
immunogen. 
In conclusion, the nitric oxide radical causes extensive damage to chromatin 
and renders it immunogenic. The antibodies against modified chromatin are 
polyspecific in nature, resembling the antigen binding characteristics of SLE 
autoantibodies. The possibility of nitric oxide modified chromatin in the production of 
SLE autoantibodies has been suggested. 
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The beautiful double helix structure of DNA was discovered in 1953 by James 
Watson and Francis Crick. DNA contains the instructions to make each one of us. Its 
digital code is similar to binary, except that instead of two alternatives (designated 0 
and 1) it contains four (designated A,C,T and G). It is the position of these four bases 
in the sequence, which generates the information to synthesize proteins. Proteins in 
turn regulates, repair, replicate and control DNA synthesis. Some proteins physically 
interact with the DNA and together they are called "chromatin". Eukaryotic cells must 
accomplish the daunting task of packaging an enormous amount of DNA into their 
nucleus, while ensuring the proper expression of a subset of genes while silencing the 
other regions of the genome. Cells accomplish this feat by packaging DNA into 
chromatin (Rountree et al., 2001). 
The nuclear matrix is an important structural component in a variety of nuclear 
functions and nuclear morphology, including DNA organization, DNA replication, 
RNA synthesis and control of these processes. DNA loop domains of chromatin are 
attached to the nuclear matrix at their base and this organization is maintained 
throughout both interphase and metaphase. These loops are 50-150 Kbp long and are 
equivalent in size to the replicon. The haploid human genome contains 3000 
megabase pairs (Mbp) of DNA with a near chromosomal size of 130 Mbp. Although 
cliromatin was historically thought of as an inert repressive structure, we now know 
that it is truly a living vibrant entity (Wolffe, 2001). Chromatin consists of DNA and 
associated proteins. There are two types of proteins in chromatin: Histones which are 
small, well defined, basic proteins, whereas non-histones chromosomal proteins 
include a large number of widely diverse structural, enzymatic and regulatory 
proteins, most of which are yet to be characterized. 
During the 1970s, a combination of physical and molecular biology techniques 
revealed that chromatin consists of a repetitive nucleoprotein complex, the 
nucleosome (Komberg, 1974). The laboratory of Pierre Chambon was the first to 
name the nucleosome (Germond et al, 1975). The nucleosome particle comprises a 
histone octamer with two copies of each of the histones H2A, H2B, H3 and H4, 
wrapped by 147 bp of DNA. In the octamer, histones H3 and H4 are assembled in a 
tetramer, which is flanked by two H2A-H2B dimers. A variable length of DNA 
completes the second turn around the histone octamer and interacts with a fifth 
histone, named HI (Ballest and Estellar, 2002). The histone octamer wrapped by 147 
bp of DNA is called as the nucleosome core particle. The DNA between the 
nucleosomes is called the linker segment. The linker segment gives unfolded 
chromatin a beads on a string appearance. Strings of linked nucleosomes are helically 
twisted into a 10 nm fibre, which in turn, is folded into a 30 nm fibre. (Dundr et al, 
2001).The average linker length is variable in different species to a maximum of 
about 100 base pairs. 
The dynamic properties of chromosome structure play key roles in multiple 
cellular processes, including gene expression, genome integrity, cell aging and cell-
cycle progression. 
Chromatin dynamics: chromatin folding and accessibility is a dynamic process 
(Cremer et al, 2000). Acetylation by histone acetyl transferases (HATS) and 
deacetylation by histone deacetylases (HADCs) alter the condensation of arrays of 
nucleosomes. Acetylated chromatin is more unfolded and, therefore more 
transcriptionally active, whereas deacetylated chromatin is repressive to transcription 
(Francastel et al, 2000). Hitone-histone interaction and accessory factors such as 
histone HI further compact nucleosomal arrays into fibers. Fibers are further 
condensed by inter-fiber interactions. Thus an individual chromatid will have regions 
of highly repressive chromatin structure along with chromatin that is less folded and 
more receptive to transcription (Manuelidis, 1984; Manuelidis, 1990). 
Beside acetylation, there are methyl CpG-binding proteins that recognize 
methylated DNA and are involved in repression of transcription. These proteins are 
shown to be chromatin associated. This class of proteins repress chromatin by either 
recruiting HDACs or interacting directly with promoter bound factors, while other 
members form complex chromatin remodeling complexes as Mi-2-NuRD complex. 
Besides, methylation of H3 tails can also recruit proteins involved in silencing. 
The N-terminal tails of histones extend from the nucleosome and are the sites 
for numerous post translational modifications. Histone H3 and H4 have several lysine 
and serine residues which are modified and might act to facilitate or trigger certain 
events as transcription, silencing, histone deposition and mitosis. 
Then there are various enzymes that are responsible for chromatin remodeling 
and gaining access to the DNA template, thus forming pre-initiation complex (PIC) at 
specific eukaryotic gene promoter sequences e.g chromatin remodeling enzymes 
(CREs) and/or HATs (Workman et al, 1998). 
However, it is typically assumed that chromatin-binding proteins are stably 
and statically bound to chromatin. While this appears to be true for the core histones 
(Phair et al, 2000; Lever et al, 2000), virtually all other chromatin-binding proteins 
and components of the transcription machinery associate only transiently with 
chromatin. The linker histone HI, which resides outside of nucleosomes but acts as a 
structural chromatin protein, is dynamically exchanged between binding sites (Lever 
et al, 2000; Misteli et al, 2000). It resides on chromatin for only a minute before it 
dissociates. Similarly, the high-mobility group proteins, associate with chromatin for 
less than 5 sees. This short period of association ensures the ability of cell to respond 
to external stimuli such as rapid changes in its gene expression programme. The 
recent observation that the remodelling activity SNF/SWI can only act on chromatin 
upon removal of histone HI confirms the theory (Hill et al, 2000). 
In himians, there have been identified various histone modifying enzymes (eg 
HDACl, PCAF) and ATP-dependent chromatin remodeling enzymes (eg RSF, 
hSWl/SNF) which alter acetylation state of histone H3 and H4 and disrupt DNA-
histone interactions, leading to mobilization of nucleosomes within chromatin fiber by 
ATP hydrolysis, respectively. 
Antigenicity of chromatin 
Chromatin has been implicated as an important target of autoantibodies in 
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idiopathic and drug-induced lupus for decades, but the antigenicity of chromatin has 
only recently been dissected (Burlingame and Rubin, 1996). Although anti-DNA 
antibodies are considered diagnostic of systemic lupus erythematosus (SLE), they are 
expressed in association with antinuclear antibody specificities, suggesting a role for 
both generalized as well as antigen specific immune abnormalities in their etiology 
(Pisetsky, 1992; 1997). The notion that DNA is immunologically inactive, derives 
primarily from unsuccessful efforts to replicate lupus by immunization of normal 
animals with DNA (Messina et al, 1993). However DNA complexes with a synthetic 
immunogenic peptide Fus-I induces an anti-double stranded DNA response in mice 
(Desai et al, 1993). This led to the conclusion that antigen - drive in lupus involves 
either a substance other than DNA or DNA in the form of nucleosomes. (Burlingame 
etal, 1993; Mohan e/a/., 1993). 
The nature of autoantigen that initiates the production of anti-double stranded 
DNA (anti-dsDNA) and anti-histone antibodies in systemic lupus erythematosus has 
remained obscure. Hardin in 1986 noted that patients with SLE responded primarily 
to external features of intact nucleosomal segments of chromatin, since the antibodies 
produced were directed to both histones and dsDNA. 
It has been suggested that in SLE, antibodies to individual histones or to 
dsDNA are minor components of the IgG anti-chromatin (anti-nucleosome) response 
(Chabre et al, 1995). Several studies have reinforced the concept that SLE is an anti-
chromatin antibody disease; e.g., that the autoimmune response is against chromatin 
with the development of antibodies directed to various epitopes on chromatin 
including but not limited to DNA (Mohan et al., 1993; Burlingame et al, 1993; 1994; 
Amoura et al, 1994; Chabre et al, 1995; Tax et al, 1995). The possiblitity that anti-
nucleosomal antibodies may generally be involved in nephritis has also been 
suggested by experimental and clinical studies (Burlingame et al, 1994; Kramers et 
al, 1994; Monestier et al, 1995; Tax et al, 1995). In a clinical study of SLE, 
antibodies to epitopes on chromatin were found to be more highly associated with 
nephritis than antibodies to DNA (Burlingame et al, 1994). The genesis of the 
immune response to chromatin in MRL/Mp-lpr/lpr mice has been investigated 
(Burlingame et al, 1993). The results demonstrated that many features of anti-
chromatin autoantibody production resemble those of an active T cell-dependent 
immunization process, and that antibodies recognize a wide spectrum of epitopes on 
chromatin. These findings imply that chromatin is the structure that initiates the 
production of anti-histone, anti-subnucleosome, and anti-dsDNA autoantibodies. It 
has been proposed that a defect in the catabolism of chromatin may render it 
immunogenic. A clear example of altered DNA/chromatin comes from examples of 
patients with drug-induced lupus. Drugs that induce lupus like side effects, have been 
proposed to act in different ways by inhibiting DNA methylation, by inducing a B-
DNA to Z-DNA transition, by generating oxidative metabolites that can cause 
massive DNA-damage resulting in release of altered types of subnucleosomes, or by 
inactivating complement C4. Some of these mechanisms may generate altered histone 
or histone/DNA epitopes, thus triggering non-tolerant Th cells (Mohan and Datta, 
1995). It has been suggested that the change of chromatin's antigencity by 
environmental factors and genetic background may be the common pathway to SLE 
pathogenesis (Lu et al, 1998). Exposure of autoimmune (NZBXNZW) F(I) mice to 
pristane, a model environmental trigger, synergistically activated the production of 
anti-chromatin/DNA antibodies and dramatically accelerated renal disease (Yoshida 
et al, 2002). Furthermore, it has been reported that chromatin may be one of the 
initiating autoantigens and the possibility that nucleosomes may also be an 
autoantigen in human SLE, is supported by several observations demonstrating the 
presence of oligonucleosome-like structures in plasma from patients with SLE 
(McCoubrey et al, 1984; Li and Steinman, 1989; Rumore and Steinman, 1990; 
Burlingame et al., 1993). The formation of anti-nucleosome antibodies and 
nucleosome-Ig complexes is a characteristic feature of MRL/lpr mice. (Licht et al, 
2001). Attempts to immunize non-autoimmune mice with nucleosomes prepared in 
vitro have failed, giving support to the notion that qualitative modifications of 
nucleosomes are necessary for autoantibody induction (Amoura et al, 1999). It has 
been shown that during apoptosis, a series of post-translational protein modifications, 
including proteolysis, phosphorylation, oxidation with heavy metal etc, may create 
modified autoantigens that might contribute to the bypass of tolerance that is required 
for autoantibody formation (Utz and Anderson, 1998). 
The highly reactive hydroxyl radical (OH) can interact with chromatin and 
result in a wide range of sugar and base-derived products, DNA-protein crosslinks 
and strand breaks (Ahsan et al, 2003). It is reported that anti-DNA antibodies found 
typically in SLE have a greater capacity to bind to ROS-modiiicd DNA (Blount et al, 
1989) (Table 1). Recent studies from our laboratory have demonstrated that after 
modification with ROS, DNA becomes highly immunogenic and the induced 
antibodies exhibit variable binding to native DNA. (Ahmad et al, 2000; Ashok et al, 
1999; Ashok et al, 1997). It has been postulated that ROS-modified DNA as a more 
discriminating antigen for the diagnosis of SLE (Ara et al, 1992; Blount et al, 1991; 
Blount et al, 1990). Monoclonal anti-DNA antibodies react more strongly with 
denatured DNA than nDNA. (Ahmad et al, 1998; Ashok et al, 1998; Wu et al, 
1990). It has been proposed that ROS generated in vivo can cause DNA damage, thus 
altering its structure and immunogenicity, resulting in the antibodies cross reactive to 
nDNA (Blount et al, 1989). The detection of 8-oxodG, a marker of oxidative DNA 
damage in the immune complex derived DNA of SLE reinforces the evidence that 
ROS may be involved in its aetiology (Lunec et al, 1994). 
Nitric oxide: A multifaceted molecule 
Nitric oxide has generated an exponential amount of research since its 
identification in 1987. During the past decade this small molecule has emerged as an 
important mediator in physiological and pathological processes (deBelder and 
TABLE 1 
Inhibition of SLE antibody binding to native DNA and ROS-DNA 
fragments of varying size 
Size of DNA 
Native DNA 
800 bp 
600 bp 
300 bp 
200 bp 
120 bp 
70 bp 
50 bp 
Mean 
SD 
% Inhibition 
Native DNA 
60 
58 
55 
65 
50 
60 
30 
30 
51 
±12.9 
ROS-DNA 
75 
76 
78 
72 
70 
72 
55 
50 
68.5 
±9.6 
Adapted from: Ara J, Ali R. Reactive oxygen species modified DNA 
fragments of varying size are preferred antigen for human anti-DNA autoantibodies. 
Immunol. Lett. 1992; 34, 195-200. 
Radomski, 1994; Dawson and Dawson, 1995; Gross and Volin, 1995; Brennan et al, 
1999). The wide variety of roles described for NO can be placed into one of three 
categories: (i) an intracellular signal, (ii) a transcellular messenger, or (iii) a cytotoxic 
species (Knowles and Moncada, 1994). Nitric oxide is formed during conversion of 
L-arginine to L-citruUine by nitric oxide synthase (NOS) in the presence of NADPH 
and O2 (Griffith and Stuehr, 1995; Chinje and Stratford, 1997). NOS exists as three 
isoforms. The calcium-dependent endothelial (eNOS) or N0S3; neuronal (nNOS) or 
NOSl and the calcium-independent inducible (iNOS) or N0S2 (Knowles and 
Moncada, 1994). Of these, iNOS may be found in macrophages, hepatocytes, 
neutrophils, endothelial cells and astrocytes. This form is important in the 
immunogenic and cytotoxic response of T lymphocytes and macrophages as well as in 
the bacteriostatic activity of reticulo-endothelial cells (Brennan et al, 1999). The 
expression of iNOS in human infections, autoimmune, and chronically inflammatory 
diseases as well as several other human disorders is well established. It is becoming 
clear that nitric oxide, including iNOS derived reactive nitrogen species, comprises 
both regulatory and effector functions (Kronke et al., 1998). Nitric oxide diffuses out 
of the cell that generates it and moves into target cells, where it interacts with specific 
molecular targets (Table 2). 
(a) Nitric oxide in cardiovascular and pulmonary systems 
Nitric oxide is known to induce smooth muscle relaxation, produced by 
endothelial cell lining of vascular tissues (Palmer et al, 1987). 
Nitric oxide acts as an endogenous autoregulator of blood flow, causing 
vasodilation (Wennmalm et al, 1990; Schror et al, 1991; Matheis et al, 1992). Nitric 
oxide regulates the systemic blood pressure and the local flow to specific vascular 
beds (Faraci and Heistad, 1992) including the brain (Toda and Okamura, 1990; 
Tanaka et al, 1991; Faraci and Breese, 1993), kidney (Baumann et al, 1992; Ribeiro 
et al., 1992; Yukimura et al, 1992; Deng and Baylis, 1993), lung (Fineman et al, 
1991), heart (Amezcua et al, 1989; Chu et al, 1990; Richard et a/., 1991; Broten et 
al, 1992; Jones and Brody, 1992) and gastrointestinal tract (Iwata et al, 1992/ 
Nitric oxide also regulates blood clotting by inhibiting platelet aggregation 
(Radomski et al, 1990b ; Pasqui et al, 1991; Vallance et al, 1992; Varela et al, 
1992; Ivanova et al, 1993) and adhesion (Radomski et al, 1987 a, b, c; Sneddon and 
Vane 1988; Siney and Lewis, 1992; de Graaf era/., 1992). 
TABLE 2 
Molecular targets of nitric oxide 
Nitric oxide target 
molecules 
Mechanism Targets 
Proteins Binding to heme iron Guanylate cylase, hemoglobin, 
NADPH-ubiquinone oxidoreductase, 
succinate-ubiquinone oxidoreductase. 
Binding to iron-sulfur Cis-aconitase, ribonucleotide reductase 
ADP ribosylation Glyceraldehyde-3 -phosphate 
dehydrogenase 
Nucleic acids Deamination DNA 
Radical molecule Superoxide 
ADP: adenosine diphosphate; NADPH: nicotinamide adenine dinucleotide phosphate. 
(b) Nitric oxide as a neurotransmitter 
Nitric oxide is a neurotransmitter in the peripheral and central nervous system, 
where it contributes to sensory transmission (Duarte et ai, 1990) and a modulator in 
non-adrenergic and non-cholinergic nerves (Rand, 1992). Nitric oxide also play a part 
in the formation of memory (Bohme et al, 1991; O'Dell et al, 1991; Schuman and 
Madison, 1991; Shibuki and Okada, 1991), in vision (Venturini et al, 1991), and 
olfaction (Breer and Shepherd, 1993) in animals. 
(c) Nitric oxide as an immune effector 
Monocyte derived macrophages (Denis, 1991a), alveolar macrophages 
(Sherman et al, 1991) and neutrophils (Moncada, 1992) can generate nitric oxide by 
inducible form of NOS. In large quantities nitric oxide kills or inhibits the growth of 
many pathogens, including bacteria (Adams et al, 1991; Denis, 1991b; Fortier et al, 
1992; Beckerman et al, 1993; Mayer et al, 1993), fiingi (Alspaugh and Granger, 
1991) and parasites (Green et al, 1990; Liew et al, 1990; Mauel et al, 1991; 
Vincendeau and Daulouede, 1991; Gazzinelli et al, 1992; Lin and Chadee, 1992; 
Munoz-Femandez et al, 1992; Rockett et al, 1992). It also kill tumour cells (Hibbs et 
al, 1988). Nitric oxide induced apoptosis (Tews and Goebel, 1998) is mediated by 
p53 expression in macrophages and pancreatic cells (Messmer et al, 1994). Nitric 
oxide generating compound, S-nitrosoglutathione induces apoptosis in human 
chondriocytes and causes necrosis like cell death in human epithelial cell line 
(Turpaev et al, 1997). It has been reported (Hortelano et al, 1997) that induction of 
apoptosis by nitric oxide is mediated via triggering mitochondrial permeability 
transition. The biochemical basis of the cytotoxicity induced by nitric oxide is its 
combination with iron-containing enzymes of the respiratory cycle and the 
inactivation of ribonucleotide reductase (Hibbs et al, 1990; Ignarro, 1991; Lepoivre 
etal, 1991;Kwone/fl/., 1991). 
Most of the cellular components as the tumour mass (tvimor cells and immvme 
cell infiltrate) have been shown to generate NO in vitro. The expression of NOS in 
neoplasms provokes the question about a physiological role for tumor associated NO 
production (Murta et al, 1999). It has been demonstrated that oxygen radicals and 
nitrogen oxide derivatives such as peroxynitrite and NO2 can effectively damage 
DNA despite the presence of multiple antioxidant defense and repair system. Such 
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damages is thought to make significant contribution to age related development of 
cancer (Maeda and Akaike, 1998). Expression of NOS has been found to be 
correlated with the grade of some human tumours such as breast, ovarian, cervix, 
gastric, head and neck cancer (Thomsen et al, 1994, 1995b; Rosbe et al, 1995; 
Thomson and Miles, 1998) and associated with enhanced metastasis (Duenas-
Gonzalesetal, 1997). 
Nitric oxide as a free radical 
Nitric oxide is a paramagnetic, diatomic and uncharged molecule with an 
unpaired electron. These characteristics of nitric oxide make it an ideal messenger 
molecule which can diffuse freely across membranes. Having an unpaired electron, it 
is called a radical molecule, which is highly reactive, having a half life of 2 to 30 
seconds (Lowenstein et al, 1994). It has been proposed that nitric oxide could be a 
candidate for endogenous human carcinogenesis, as a result of mutations in DNA 
arising following nitric oxide induced deamination (Cooper and Krawczak, 1990; 
Hirschbom et al, 1990; Perutz, 1990; Keefer et al, 1991; Nguyen et al, 1992). 
Saturated solutions of nitric oxide have been demonstrated to deaminate 
deoxyribonucleosides, nucleotides and calf thymus DNA under aerobic environment 
in vitro (Keefer et al, 1991). 
The prediction that nitric oxide might damage DNA followed from the 
recognition that it can diazotize primary arylamines (ArNH2) nitrosatively in an 
oxidizing environment (Ji and Bellocher, 1988; Rait et al, 1988; Kosaka et al, 1989) 
(Eq. 1). Since hydrolysis of the diazonium ion product replace the nitrogen substituent 
by oxygen (Eq. 2) it was reasoned that diazotization and hydrolysis of cytosine and 
other DNA bases in vivo as depicted in Eqs. 3-6 might lead to heritable genetic 
alterations. 
ArNHz + NO •ArNj^ + H2 O (1) 
(ox) 
ArN2^  + H2O • ArOH + N2 + H* (2) 
-e" 
dC + NO • dU + N2 + H^ (3) 
pH7.4 
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-e 
m^ dC + NO • ( ! ! + N2 + H^ (4) 
pH7.4 
-e' 
dG + NO • d X + N2 + H'' (5) 
pH7.4 
dA + NO • dl + N2 + H^ (6) 
pH7.4 
Observed DNA sequence changes were found (Keefer et al, 1991) on treating 
Salmonella typhimurium TA 1535 in vivo with nitric oxide, there were > 99% C—> T 
transitions, consistent with a cytosine deamination mechanism. The vast majority 
(99%) of mutations found were CG —>TA transitions. Similarly, deamination of 
guanine and adenine to xanthine and hypoxanthine respectively on exposure of human 
cells to nitric oxide in vitro lead to GC —^ > AT transitions (Nguyen et al, 1992). The 
GC — >^ AT transition arises as a result of insertion of dA opposite dU, following 
deamination of dC (Duncan and Miller, 1980) or by the insertion of dT opposite dX, 
following deamination of dG (Eritja et al, 1986). Two direct acting mutagens namely 
N-nitroso-2-fluronylacetamide and N-nitroso-3,5-dinitro-acetaminophen develop their 
genetoxicity by release of nitric oxide free radical (Lin et al, 1993a). Purines were 
more readily deaminated than pyrimidines. Nitric oxide attacks guanine bases, as the 
most preferential cleaving sites and the frequency of the nitric oxide induced cutting 
decreases in the order G>C>A>T. The preferred cleavage at GC sequences by nitric 
oxide may correlate to predominant mutagenicity at GC sites by nitric oxide (Sugiura 
and Matsumoto, 1995). 
Another possible route of nitric oxide toxicity is its interaction with 
superoxide anion (OJ) to form secondary species which make a greater contribution 
to DNA damage. The secondary species can react with other cellular constituents to 
form tertiary species which may also cause DNA damage (Fig. 1). Biosynthesis of 
nitric oxide may lead to the production of reactive oxynitrogen intermediates such as 
nitrosonium (NO" )^, nitroxyl ions (NO), nitrogen dioxide (NO2), peroxynitrite 
( 0 N 0 0 ~ ) and S-nitrosothiols (Stamler et al, 1992). Simultaneous generation of O2 
and nitric oxide can lead to the production of 0 N 0 0 ~ and hydroxyl ion which can 
cause considerable damage to host cells (Beckman et al, 1990; Inoue and Kawanishi, 
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Primary 
species 
Nitric Oxide 
+O5 
Secondary 
species 
N2O3 
ONOO' 
Tertiary species 
Nitrosamines 
-• Glucose 
adducts 
-• Nitrosothiols 
Fig. 1: Nitric oxide as a primary, secondary or tertiary mutagen. Possible 
DNA-damaging species are highlighted. 
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1995) as well as antioxidant depletion in human body fluids (van der Vliet et al, 
1994). Peroxynitrite can oxidize variety of biomolecules including both protein and 
non-protein thiols (Radi et al, 1991), protein sulfides (Moreno and Pryor, 1992; Pryor 
etal, 1994), lipids (Moncadae/a/., 1991) and deoxyribose (Beckman eM/., 1990)./« 
vivo peroxynitrite induce the formation of two adducts: 8-nitroguanine (Yermilov et 
al, 1995) which is depurinated to form an apurinic site, a lesion which could 
potentially induce G-^T transversion. The other adduct is 4,5-dihydro-hydroxyl-4-
(nitrosooxy)-2'- deoxyguanosine (Douki et al., 1996). It can also cause nicks in the 
supercoiled plasmid DNA (Pryor et al, 1995). Cigarette tar and nitric oxide act 
synergistically to induce DNA strand breakage (Ohshima and Yoshie, 1997). The 
inducible isoform of nitric oxide synthase (iNOS) and 3-Nitrotyrosine, a marker of 
peroxynitrite damage has been demonstrated by immunohistochemistry in neoplastic 
rat liver tissue (Ahn et al, 1999). 3-Nitrotyrosine was observed in the cytoplasm of 
some living or apoptotic hepatocellular carcinoma cells, cormective tissues etc of 
tumorous hepatocytes and cholangiomas in tumors, suggesting a role of NO and 
peroxynitrite in the development and/or growth of tumor tissues. Elevated levels of 3-
Nitrotyrosine has been found as well in sera of SLE patients (Gilkeson et al, 1999). 
Peroxynitrite when protonated decomposes rapidly resulting in the formation of 
hydroxyl radical and nitrogen dioxide, both of which are tissue damaging agents and 
cause DNA strand breaks (Moncada et al, 1987; Beckman et al, 1990; Moncada et 
al, 1991; Wang etal, 1991; Ischiropoulos etal, 1992; Felley-Bosco, 1998; Thomas 
et al, 1998). NO along with H2O2 produce hydroxyl radical (OH) as biologically 
feasible, alternate mechanism for initiating cytotoxic activity in the absence of 
superoxide - mediated Fenton reaction due to nonavailability of "free" catalytic 
metals in cellular milieu for direct interaction with ROS (Simonian et al, 1996; Nappi 
andVass., 1998). 
The major candidates for the DNA-damaging activity of nitric oxide in cell are 
nitrous anhydride and peroxynitrite (Koppenol et al, 1992; Tannenbaum et al, 1994) 
(Fig. 2). Nitrous anhydride can cause nitrosative deamination of bases. N-
nitrosamines can be formed from reaction of nitrous anhydride with primary amines 
(Lewis et al, 1995; Liu and Hotchkiss, 1995). Aerobic gaseous nitric oxide was 
shown to generate primarily AT —> GC transitions. Whereas aqueous nitric oxide 
derived from nitric oxide donor compounds, generate largely GC —> AT transitions. 
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DNA damage by N2O3 and peroxynitrite 
N2O3 Peroxynitrite 
Guanine 
fragmentation 
Oxidized 
guanine 
DNA 
crosslinks 
8-Nitro-dG 
Deaminated 
bases 
I 
Abasic 
sites 
Oxidized Abasic 
deoxyribose sites 
Single-strand 
breaks 
Fig. 2: Overview of DNA damage pathways resulting from nitrogen free 
radicals 
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In the presence of nitrosating agent N2O3, deamination resulted in the formation of 
xanthine and uracil at G:C base pair, respectively. Xanthine was formed at twice the 
rate of uracil, while single stranded oligomers were found to be five times more 
reactive than deoxynuclesides toward N2O3. (Caulfield et al, 1998). 
Mutations in mitrochondrial DNA (mtDNA) have recently been associated 
with a variety of himian diseases. MtDNA damaged by NO resulted in lesions 
produced mainly by deamination of guanine to xanthine, while specific adenine bases 
were also damaged. Most of the lesions produced by NO were repaired rapidly. 
However, there appeared to be a subset of lesions which were repaired either slowly 
or not at all by the mitochondria (Grishko et al, 1999). NO exposure also leads to 
DNA single strand breaks (Kolb et al, 1993). In addition to DNA damage it has been 
reported that nitric oxide also causes inhibition of various DNA repair enzymes (Park 
and Aust, 1998) namely; Fpg protein (formamidopyrimidine-DNA-glycosylase) 
(Wink and Laval, 1994) and O -^methyl guanine-DNA-methyl transferase (Laval and 
Wink, 1994). Nitric oxide also inhibits DNA ligase activity (Graziewicz et al, 1996). 
The inliibition of DNA ligase may explain the increase in strand breaks reported for 
cells exposed to nitric oxide and provide explanation for increase DNA lesions 
without its direct chemical modification by nitric oxide. Further, NO and peroxynitrite 
inhibit DNA-adduct excision repair in human fibroblasts (Chien et al, 2004). 
Antioxidants 
Humans are exposed to a wide range of nitrogen containing compounds and 
nitrosating agents e.g. nitrite, nitrate, and nitrogen oxides (NOx), that can react in vivo 
to form potential carcinogenic N-nitroso compounds (NOCs) or reactive diazo 
compounds. Endogenous nitorosation can occur at many locations in the body 
including sites of chronic infection or inflammation. In addition, over production of 
NO leads to increase levels of peroxynitrite, aldehydes and epoxides derived from 
lipid peroxidation, yielding miscoding exocyclic DNA adducts. (Fig. 3) 
Thus, various substances eg ascorbic acid, a - tocopherol are known to inhibit 
NOC formation by destroying nitrosating agents (Bartsch and Frank, 1996). 
• Blocking the inducible NO synthase by L-arginine analogues and curcumin 
has been reported. (Broust and Oshima, 1995). While strengthening the 
cellular defense system against oxidative stress by increasing superoxide 
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dismutase, catalase or glutathione peroxidase activities by means of various 
inducers should inhibit NO/(NOx) - associated damage. 
• Since the original discovery by Mirvish et al, (1972), the blocking effect of L-
ascorbic acid and ascorbate on NOC formation have been demonstrated in 
many in vitro and in vivo systems (reviewed by Mirvish, 1986; Bartsch et al, 
1988). Ascorbic acid and the ascorbate anion inhibit NOC formation over a 
wide pH range of 2-5 in aqueous solution by rapid reduction of nitrous acid to 
nitric oxide and production of dehydroascorbic acid. 
• a -Tocopherol, the principal component of vitamin E, reduces nitrite to nitric 
oxide and is excellent inhibitor of N-nitrosation in lipids and emulations in 
water. Simple phenols and phenolic compounds can reduce the rate of NOC 
formation, depending on their structure and the reaction conditions (Pignatelli 
etal, 1982). 
• Monitoring urinary levels of N-nitrosamino acids such as NPRO (the NPRO 
test) have shown the inhibitory effects of betel nut extracts, caffeic and ferulic 
acids and coffee and tea on the endogenous nitrosation of proline in human 
subjects (Stich et al, 1983, 1984). In addition, inhibitor}' effects of vegetable 
and fruit juices, alcoholic beverages, millc and milk products, soybean 
products have been reported (Pignatelli et al, 1984). The genotoxicity of 
endogenously formed N-nitrosamines from secondary amines and sodium 
nitrite (NaNOa) have been evaluated (Ohsawa et al, 2003). Ascorbic acid 
reduce the liver damage induced by morpholine and NaNOa. However, 
reductions in hepatic genotoxicity of endogenously formed N-
nitrosomorpholine by tea polyphenols, such as catechins and theoflavins, and 
fresh apple, grape and orange juices were more effective than ascorbic acid 
alone. 
Autoimmunity 
The ability to distinguish self from non-self is a seminal feature of the immune 
system. Central T-cell tolerance to self-antigens is mediated either by elimination or 
frinctional inactivation of self-reactive lymphocytes (Zouali, et al, 1993). Disruption 
of self-nonself discrimination leads to autoimmunity (Deodhar, 1992). Autoimmunity 
is a state wherein the host mounts an immune response to self There are at least four 
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possible immune states in an autoimmune response (Brickman and Shoenfeld, 2001). 
During immunological disbalance, as a result of internal threat, the body's own tissue 
components become reactive and may result in the initiation of autoimmune 
process/diseases (Deodhar, 1992). Autoimmunity, namely the ability to recognize 
various forms of self, is a normal function of the immune repertoire. In contrast, 
autoimmune disease is the clinicopathologic state wherein the host mounts a 
detrimental response to self (Brickman and Shoenfeld, 2001). The generation of 
autoimmunity is multifaceted process in which the role of the autoantigen needs to be 
carefully defined (Zouali et al., 1993). Autoimmune diseases are characterized by 
more or less systemic chronic inflammatory processes, possibly leading to tissue 
damage (Lorenz et al., 2001). 
Factors associated with autoimmune diseases 
Autoimmune disease is multifactorial. The factors contributing to the 
development of such diseases continue to expand. The major factors associated with 
the development of autoimmunity maybe divided into genetic, immunologic, 
hormonal and envirormiental (Brickman and Shoenfeld, 2001). 
(i) Genetic factors 
Autoimmune diseases show a highly significant familial predisposition 
(Hochberg, 1987; Amett, 1992). The involvement of genetic factors has been linked 
to the human lymphocyte antigen (HLA) system, particularly the HLA-DR sublocus. 
The initiation of an autoimmune response requires that the self-reactive T cells 
interact with self-antigen and HLA class II antigen complex with sufficient avidity for 
the development of autoantibody in subsequent autoimmune disease. The association 
between certain autoimmune diseases and HLA antigens (Braun and Zachary, 1988) 
such as DR2 and DR3 in SLE, DR2 and DR3 in Sjogren's syndrome, DR4 and DR3 
in insulin dependent diabetes mellitus, DR3 in Grave's disease, DR3 in myasthenia 
gravis and DR4 in rheumatoid arthritis are well documented. It is to point out that 
genetics alone is not the final determinant of autoimmune disease development 
(Brickman and Shoenfeld, 2001). 
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(ii) Immunologic factors 
Malregulation of immune system depends on multiple components of 
feedback regulation system including T cells, B cells and idiotypes (Shoenfeld and 
Schwartz, 1984). The increased T-helper/T-suppressor cell ratio had been noted in a 
wide variety of autoimmune diseases, such as, SLE, Sjogren's syndrome, PSS or 
scleroderma, rheumatoid arthritis, pernicious anaemia, multiple sclerosis, immune 
complex mediated renal disease, immunologic skin disease and many others. 
Immunologic cross reactivity and molecular mimicry has been an important 
phenomenon in autoimmune diseases. It has been suggested that the degree of 
sequence conservation between host and a given infectious agent, heat shock proteins, 
molecular mimicry etc. may provide the link between infection and subsequent 
autoimmunity. 
Some persons may mount an immune response against self while others do 
not, because HLA molecules from different individuals display different portions of 
the antigen to T cells. Polyclonal B cell activation has been proposed as one possible 
mechanism that may be responsible for the over-activation of B cells and production 
of autoantibodies in certain autoimmune disease, particularly SLE (Dziarski, 1988; 
Klinman et al, 1990; Steinberg, 1992). While this may also occur under the influence 
of exogenous or endogenous polyclonal activators like Epstein Barr Virus (EBV) and 
its components as well as endotoxin or lipopolysaccharide (LPS), certain bacterial 
agents and drugs. 
One hypothesis called as the 'modified self hypothesis suggests that 
autoimmunity may arise as a result of an immune response against modified self 
determinants (neo-self determinants) such as new determinants created on somatically 
mutated antibodies during the maturation of the immune response e.g rheumatoid 
factors (RFs) induced transiently during an immune response, wherein glycosylation 
defects in IgGs have been proposed (Tsuchiya et al, 1993). Complement deficiencies 
(Fries et al, 1986) associated with particular HLA phenotypes resulted in slow 
clearance of immune complexes (Frank et al, 1983). "Nephritic factor" referring to 
an antibody against neo-antigenic determinations reveals the complement protein C3 
during complement activation (Spitzer et al, 1992). Other possibilities may include 
the binding of drugs or other hapten groups to self-molecules, and gene mutations. 
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Manifestations of autoimmunity are often complex and heterogeneous. It has 
been postulated that immune response against host antigens could result from genetic 
predisposition, exaggerated random B cell activity, cross-reactivity between foreign 
and host antigens. The foreign antigens arise as a consequence of infection, 
inflammation, drug administration, environmental factors, free radicals (Dixit et al, 
2001;Islam et al. 1998; Tasneem et al, 2001; Lindahl, 1993; Alam et al, 1999; Ara 
et al, 1993 Naparstek, 1993) and scores of other modifying agent. ROS have gained 
considerable interest in recent years as plausible causative agents in the pathogenesis 
of several human degenerative diseases. (Imlay et al, 1988). The OH is generated in 
substantial amounts in chronic inflammatory conditions due to increased oxidative 
stress. Lymphocytes isolated from patients suffering from rheumatoid arthritis (RA) 
and SLE contain increased levels of 8-oxo-dG (Lunec et al, 1994; Bashir et al, 
1993). A study on blood monocytes isolated from SLE patients indicated an 
impairment in the removal of 8-oxo-dG from cellular DNA due to a deficient repair 
system, that may result in cell death and release of oxidized DNA. ROS have been 
known to cause damage to DNA and their relevance in the induction and development 
of cancer is well documented (Ashok et al, 1998; Juenje, 1989; Stich et al, 1989; 
Meneghini et al, 1988). These radicals have also been implicated as causative agents 
of ageing (Ashok et al, 1999) and of several human diseases including multiple 
sclerosis, Parkinson's disease and autoimmune disorders (Ames, 1989; Marx, 1987; 
Halliwell et al, 1987). It has been proposed that in chronic inflammatory diseases 
such as RA and SLE, DNA-anti-DNA antibody complex(es) deposit in tissues and 
induce inflammation (Naparstek et al, 1997). The phagocytic cells may then release 
ROS at the site of injury (Allan et al, 1988). These oxygen species being highly 
reactive may penetrate cellular membranes and react with nuclear DNA (Lunec et al, 
1987; Stollar, 1981). 
(Hi) Hormonal factors 
Hormones are a significant factor in the development of autoimmune disorders 
(Lahita, 1999). Patients bom with Klinefelter's syndrome, a feminizing genotype, also 
have an unusually high prevalence of lupus (Ortiz and LeRoy, 1969). In humans as 
well as in animal models, some autoimmune diseases show a predilection for males 
rather than for females. Danazol, a semi-synthetic androgen occasionally used in 
treatment of autoimmune disorders, may induce lupus in some patients (Guillet et al, 
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1988). Other hormones including progesterone (van Vollenhoven and McGuire, 1994) 
and prolactin (Walker et al, 1998) appear to have immuno-regulatory properties. 
(iv) Environmental factors 
Environmental factors have been implicated in autoimmime disease including 
infectious agents, medications, chemicals, toxins and ultraviolet light to name but a 
few (Aharon and Shoenfeld, 1998; Saraux et al, 1999). Smoking and obesity may 
increase the risk of RA (Karlson et al, 1999; Shovman and Shoenfeld, 2000). Here 
the multifactorial nature of autoimmune disorders also become evident while 
ultraviolet light is known to trigger lupus (McGrath, 1999), it has been very 
effectively used to treat psoriasis, another autoimmune disease (Halpem et al, 2000). 
D-pencillamine, a medication formerly used to treat several immune disease 
including RA, scleroderma and primary biliary cirrhosis, have been implicated in the 
development of autoimmune diseases such as lupus and glomerulonephritis (Brik et 
al, 1995). Physical and psychological stresses have also been implicated in the 
development of autoimmune disease (Gaillard and Spinedi, 1998). 
Since no single theory adequately explains the development of all autoimmune 
diseases therefore, it may be stated that the evolution from autoimmunity to 
autoimmune disease is multifactorial (Brickman and Shoenfeld, 2001). 
Autoimmune diseases may be classified, somewhat arbitrarily, into organ 
specific and systemic autoimmune disease (Table 3). There are autoimmune diseases 
in which the autoantigen is known, like myasthenia gravis (acetylcholine receptor), 
Grave's disease (TSH-receptor), or disseminated encephalomyelitis (myelin basic 
protein). Damage due to inflammatory processes is seen more often in systemic 
diseases than organ-specific diseases. 
In systemic autoimmune diseases, individuals develop autoantibodies directed 
against a variety of cellular components. It is remarkable that a particular set of 
autontibody specificities is associated with each disease. Hence, these autoantibody 
profiles constitute a usefiil and valuable tool in their diagnosis. Some of these 
autoantibody specificities show a unique disease-restriction such as the anti-Sm 
autoantibody found exclusively in the sera of SLE patients. Other specificities show a 
broader association, such as anti-UlRNP antibody found in high litres in patients with 
MCTD and in low titres in SLE (Rokeach and Hoch, 1992). This clinical and 
serological heterogeneity has been identified and characterized in detail that is 
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TABLE- 3 
Classification of autoimmune diseases 
Organ specific autoimmune diseases 
Grave's diseases 
Hashimoto's thyroiditis 
Rheumatoid arthritis 
Myasthenia gravis 
Pernicious anemia 
Addison's disease 
InsuHn dependent diabetes mellitus 
Primary biliary cirrhosis 
A-utoimmune hepatitis 
Autoimmune hemolytic anemia 
Idiopathic thrombocytopenic purpura 
Autoimmune gastritis 
Multiple sclerosis 
Ulcerative colitis 
Systemic/non-organ specific autoimmune diseases 
Systemic lupus erythematosus Systemic vasculitis 
Sjogren's syndrome Behcet's disease 
Progressive systemic sclerosis Antiphosholipid syndrome 
Mixed connective tissue disease Polymyositis/Dermatomyositis 
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associated with specific autoantibodies. Thus, antibodies to DNA have been linked 
closely to nephritis. Antibodies to UlRNP are found in SLE without nephritis and the 
overlapping syndrome of scleroderma, myositis, SLE or MCTD. Antibodies to 
histone are associated with drug-induced SLE, neonatal lupus erythematosus, SLE-
Sjogren's syndrome overlap, antinuclear antibody (ANA) negative SLE and Sjogren's 
syndrome (Reichlin and Harley, 1987) (Table 4). 
Role of nitric oxide in autoimmunity 
Nitric oxide is an important mediator of inflanmiatory response. It is a strong 
pro-inflammatory substance (Kiechle and Malinski, 1993; Lowenstein et al, 1994) 
that may increase vascular permeability in inflammed tissue (Mayhan, 1992) and 
increase the potential of cells to produce hydrogen peroxide (Margrinat et al, 1992). 
Nitric oxide augments the inflammatory responses in sepsis by increasing the 
production of cytokines (Van Dervort et al, 1994), e.g. tumor necrosis factor and 
interleukin-I (Lander et al, 1993). Elevated nitric oxide biosyntheis has been 
associated with chronic inflammatory autoimmune diseases including rheumatoid 
arthritis, inflammatory bowel disease and multiple sclerosis (Cook and Cattell, 1996; 
Rnangetal, 1996; Parkinson era/., 1997; van deer Veen e/a/., 1997; Fenyk-Melody 
et al, 1998). Patients with rheumatoid arthritis over express NOS and overproduce 
nitric oxide (Farrell et al,1992; Sakurai et al, 1995; St. Clair et al, 1996). Nitric 
oxide generation as a predictive parameter of acute allograft rejection has also been 
reported (Devlin era/., 1994). 
(a) Cells that produce nitric oxide in autoimmune disease 
Macrophages and PMN cells, which are known to produce relatively large 
amounts of nitric oxide after induction of NOS via lymphokines, releases nitric oxide 
at the inflammatory lesions of autoimmune diseases (Kolb and Kolb-Bachofen, 1992). 
As seen in MRL Ipr/lpr mice have increased number of peritoneal macrophages as 
compared in mice of other strains (Dang-Vu et al, 1987; Clancy et al, 1995; Tamir et 
al, 1995; Huang et al, 1996). In addition to lymphocytes (Kirk et al, 1990), human 
neutrophils (Moncada, 1992) and chondrocytes (Bianco et al, 1995) can generate 
nitric oxide after induction of NOS. Infiltrating macrophages, resident endotheiiai 
cells, astrocytes (Hewett et al, 1993) or microglial cells (Zielasek et al, 1992) in the 
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central nervous system of animals with EAE may secrete nitric oxide as well (Lin et 
al, 1993b). 
(b) Action of nitric oxide in autoimmune disease 
The effect of nitric oxide in autoimmune inflammatory reaction is its direct 
toxicity on cells. The nitrosation lead to inhibition of mitochondrial electron transport 
complexes I and II (Stadler et al, 1991), inhibition of aconitase activity (Welsh and 
Sandler, 1992) and of ribonucleotide reductase, the rate limiting step in DNA 
synthesis (Nussler and Billiar, 1993). Nitric oxide can also damage DNA directly by 
deamination of purine and pyrimidine bases resulting in mutations and strand breaks 
(Lowenstein et al, 1994). Apoptosis is an important mechanism of cell destruction by 
nitric oxide. Nitric oxide forms peroxynitrite through interaction with superoxide. 
Peroxynitrite spontaneously produce highly reactive hydroxyl radical leading to cell 
damage (Beckman et al, 1990). Peroxynitrite induces cytotoxicity by generating 
DNA strand breakage which is an obligatory stimulus for the activation of poly 
(ADP-ribose) synthetase (PARS), a nuclear enzyme that consumes oxidized 
nicotinamide adenine dinucleotide (NAD"^ ) and depletes cellular ATP which is 
consumed in its regeneration leading to cell death by energy depletion (Eliasson et al, 
1997; Cookson et al, 1998; Kennedy et al, 1998). Table 5 show implications of nitric 
oxide in some autoimmune diseases. 
Systemic lupus erythematosus 
Systemic lupus erythematosus (SLE) is a systemic autoimmune disorder 
characterized by a marked diversity of organ involvement and fluctuations in disease 
activity (Min et al, 2002). It is a relatively common non-organ specific disease. It is 
characterized by inflammatory skin lesions and multiple organ damage. In 60-70% of 
cases, renal involvement complicates the systems and its severity largely determines 
prognosis (Zouali, 2001). Since these systems are associated with autoantibody 
production against a myriad of nuclear antigens, SLE has become a prototype of 
systemic autoimmune diseases (Hahn, 1998; Davidson and Diamond, 2001). With 
prevalence comparable to that of multiple sclerosis, it predominantly affects women, 
with a female/male ratio of approximately 9/1 (Zouali, 2001). SLE is the most 
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TABLE 5 
Implication of nitric oxide in some autoimmune disease 
Disease Species Treatment Nitric oxide 
with NOS or nitrite 
inhibitor production 
Refrences 
Experimental allergic Mouse 
encephalomyelitis Rat 
(EAE) 
Yes Yes MacMicking et ah, 1992; 
Unetal, 1993 b; 
Ludowyk er a/., 1993; 
Koprowski e/a/., 1993; 
Cross et a/., 1994; Hooper 
etal. 1995; Zhao era/., 
1996; Dinger a/., 1997; 
1998;Okudae/a/., 1998; 
Sahrbachere/fl/.. 1998. 
Experimental neuritis 
(adoptive) 
Diabetes, spontaneous 
Diabetes, induced by 
streptozotocin 
Lupus-like syndrome 
Arthritis 
Rheumatoid arthiritis 
Ulcerative colitis 
Rat 
Mouse 
Rat 
Mouse 
Mouse (MRL-
Ipr/lpr) 
Mouse 
Rat 
Man 
Man 
Yes 
Yes 
Yes 
Yes 
Yes 
No 
No 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Liew, 1994. 
Corbett e/a/., 1993; 
Kleemann e/a/., 1993; 
Lee 1994; Stevens et al, 
1994 
Kolbe/a/., 1991;Lukic 
et al, 1991; Cantanzaro 
etal, 1994 
Weinberg e/a/., 1994; 
Kuhne/a/., 1998. 
lalenti e/a/., 1993; 
McCartney er fl/., 1993; 
Connor e/a/., 1995 
Farrellera/., 1992 
Lundberg er a/., 1994; 
Oudkcxetal, 1995 
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representative of all autoimmune diseases because it may affect any organ of the body 
and display a wide range of clinical manifestations (Cervera et al, 1993) and various 
immunologic disorders, including production of autoantibodies, formation of immune 
complexes, decreased serum complement levels, and lymphocytopenia (Kato et al, 
2000). 
SLE is characterized by the production of a variety of autoantibodies against 
nuclear, cytoplasmic and cell surface antigens. The cellular and molecular 
mechanisms that are responsible for the production of antinuclear antibodies in this 
disease and the way in which these antibodies participate in tissue destruction remain 
highly controversial (Raviranjan et al, 2001). 
One of the first autoantibody populations characterized early was antibodies to 
native DNA, which are strongly correlated with the diagnosis of SLE (Tan, 1989). In 
1997, the discovery of autoantibodies reactive with DNA celebrated its 40"^  
anniversary. Over these four decades, perhaps no other single spontaneously produced 
autoantibody has drawn such a wide scientific interest from basic immunologists and 
clinicians particularly with respect to the mechanisms that lead to anti-DNA antibody 
formation and pathogenicity in systemic lupus erythematosus (Antonio et al, 1998). 
As structural studies with a growing number of monoclonal anti-DNA antibodies have 
progressed, it has emerged that anti-dsDNA antibodies have all the characteristics of 
those produced in an antigen-stimulated secondary immune response. They are 
predominantly of IgG isotype, are highly oligoclonal, and have numerous somatic 
mutations in their VH regions, features typical of an antigen driven response (Eilat and 
Fischel, 1991; Tillman et al. 1992; Radic and Weigert, 1994). 
Autoantibodies to histones were found to be present as often as anti-DNA 
antibodies in SLE (Gioud et al, 1982; Hardin and Thomas, 1983; Monestier and 
Kotzin, 1992). Several studies have demonstrated that anti-native DNA antibodies are 
commonly copresent with anti-histone antibodies in SLE sera (Costa and Monier, 
1983; Krippner et al, 1984; Kohda et al, 1989). Anti-histone antibodies may react 
with each of the five histones (Hardin and Thomas, 1983; Portanova et al, 1987; 
Muller et al, 1989; Monestier and Kotzin, 1992) and with H3-H4 and H2A-H2B 
complexes as well (Burlingame et al, 1994). 
The concomitant presence of autoantibodies to histones and to DNA in the 
same individual led to the early hypothesis that these two populations were linked sets 
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of antibody and was induced by a unique antigen composed of both dsDNA and 
histones (Hardin, 1986). 
Serum antibodies reacting with chromatin or its predominant components, 
histones and DNA, have been found in SLE, drug induced lupus, several other human 
disease states and in murine models of SLE (Schwartz and Stollar 1985; 
Theofilopoulos and Dixon, 1985; Costa and Monier, 1986; Fisher et al, 1988; 
Portanova et al, 1988; Burlingame and Rubin, 1991). Several studies have 
demonstrated that the autoimmune response is against chromatin with the 
development of antibodies directed to various epitopes on chromatin including but not 
limited to DNA (Burlingame et al., 1993; 1994; Mohan et al., 1993; Amoura et al, 
1994; Chabre et al, 1995; Tax et al, 1995). A central role for chromatin in 
autoimmime response to histones and dsDNA in human lupus has been suggested 
(Burlingame et al, 1994). It has been suggested that the nucleosome, the fundamental 
repeating unit of chromatin, could be a major autoantigen in lupus. Circulating 
nucleosome oligomers (180-200bp) have been demonstrated in the plasma of SLE 
patients.(Rumore and Steinman, 1990). Studies have revealed that anti-nucleosome 
antibodies occur early in life, before the emergence of anti-dsDNA and anti-histone 
antibodies (Burlingame et al, 1993; Amoura et al, 1994). 
Three congenic strains carrying lupus susceptibility genes (Slel-Sle3) from 
the lupus prone NZM2410 mouse on the C57BL/6 background were created with their 
component phenotypes characterized. Slel mediates the loss of tolerance to nuclear 
antigens; Sle2 lowers the activation threshold of B cells and Sle3 mediates a 
dysregulation of CD4* T cells. The results indicated the loss of tolerance to chromatin 
mediated by Slel is essential for disease pathogenesis and the coexpression of Slel, 
Sle2 and Sle3 as a B6-triple congenic results in severe systemic autoimmunity and 
fully penetrant, fatal glomerulonephritis (Morel et al, 2000). The nucleosome (or 
chromatin) is emerging as the most reactive substrate among the nuclear antigens, 70-
80% of SLE patients being positive (Burlingame et al, 1994; Wallace et al, 1994 
Chabre et al, 1995; Lefkowith et al, 1996; Amoura et al, 1997). Anti-nucleosome 
antibodies might be a good marker of anti-DNA negative SLE cases (Amoura et al, 
1999; Mine/a/., 2002). 
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SLE pathogenesis and apoptosis 
A major mechanism by which nuclear antigens are generated and released in 
vivo is by the process of programmed cell death (apoptosis) (Bell et al, 1990). There 
has been a hypothesis that accelerated apoptosis of circulating lymphocytes occurs 
under certain circumstances in SLE patients. Consequently, this increased rate of 
apoptosis could lead to an overflow of the phagocytic system with apoptotic cell 
material and thus increased nuclear components both normal and modified e.g. 
dsDNA, nucleosomes, or histone in serum of these patients. This intracellular or 
nuclear material would be presented to and recognized as nonself antigens by immuno 
competent cells, leading to the formation of autoantibodies (Gabler et al, 2003; 
Ahsan et al, 2003). 
Thus alteration occurring during apoptosis (Casciola-Rosen, et al, 1999; 
Rosen et al, 1999), might render these nucleosomes immunogenic. It have indeed 
been found that histones are deacetylated (H4) or dephosphorylated (HI and H3) in 
contrast to nuclear-derived histones which are acetylated or phosphorylated (Gabler et 
al, 2001). Further, 55% of SLE patients had already anti-dsDNA antibodies in their 
serum before diagnosis (Arbuckle et al, 2001) and this fluctuates in parallel with 
disease activity (Davis et al, 1977) and these patients with high dsDNA titers were 
more prone to renal disease than those without (Arbuckal, 2001). It has been found 
that these autoantibodies bind to the glomerular basement membrane either alone or 
with antigen (dsDNA, nucleosome, histone). Formation of antigen/antibody complex, 
thereby cause inflammation and tissue damage in the kidney (Lorenz et al, 2000). In 
this view, it is interesting to note that there is a correlation between SLE disease 
activity and the rate of lymphocyte apoptosis in culture (Emlen et al, 1994). This 
suggests that a higher apoptosis rate may lead to the production of autoantibodies, 
triggering disease activity (Gablar et al, 2003). 
It is observed that in vitro cultured PBMC from a subset of SLE patients 
contained higher amounts of cell debris as compared to normal healthy donors 
(Gabler et al, 2001). Along with this a lower ratio of macrophages from SLE PBMC 
containing phagocytosed apoptotic nuclei compared to macrophages from normal 
donors was found. Further, a sub-group of SLE patients showed no proper clearance 
of apoptotic cells by macrophages within germinal center of lymph node (Baumann 
et al, 2002). Thus, these events (dysregulated apoptosis and/or phagocytosis) may 
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trigger and provide survival signals for autoreactive B cells (Lorenz et al, 2000; 
Berdenera/., 1999). 
Molecular studies of autoantibody genes revealed that in both human disease 
and in experimental models of lupus, production of autoantibodies is antigen driven 
(Shlomchik et al, 1990; Manheimer-Lory et al., 1991; Winkler et al, 1992; Zouali, 
1992; 1997). Autoantibodies and B cells have been in the lupus limelight for decades, 
but now T cells have been studied extensively in SLE (Spronk et al, 1996). Various T 
cell abnormalities have been observed in SLE (Tsokos, 1992; Horwitz and Stohl, 
1993; Via and Handwerger, 1993; Dayal and Kammer, 1996; Datta et al, 1997a; 
Horwitz, 1997; Kovacs, 1997). The T cells of patient with SLE showed impaired in 
vitro proliferation in response to mitogens, antigens and allogenic major 
histocompatibility complex (MHC) molecules (Via and Handwerger, 1993; Dayal and 
Kammer, 1996; Datta era/., 1997a; Horwitz, 1997). 
The complement system also plays role in SLE. Accquired complement 
deficiency is a common finding in SLE. Measurement of classic pathway complement 
components is important in the diagnosis of SLE and for monitoring of immune 
complex mediated manifestations especially proliferative glomerulonephritis (Sturfelt, 
2002). 
Nitric oxide in SLE 
There is an evidence for a pathological role of nitric oxide in inflammatory 
diseases (Bagasra et al, 1995; Buttery et al, 1996; Parkinson et al, 1997; van deer 
Veen et al, 1997). Lowenstein et al (1994) postulated that DNA damage by nitric 
oxide may affect the development of autoimmune diseases. Subsequent release of 
altered DNA during apoptosis may enable it to act as an antigen inducing antibodies 
crossreacting with nDNA (Herrmaim et al, 1996; Casciola-Rosen and Rosen, 1997). 
Further apoptosis is an important mechanism of cell destruction by nitric oxide 
(Burkart et al, 1994; Zettl et al, 1997). It has been showed in our laboratory that 
immunization of nitric oxide modified plasmid DNA induces antibodies that exhibit 
polyspecificity and resembles the antigen binding characteristics of SLE anti-DNA 
autoantibodies (Dixit and AH, 2004). 
Nitric oxide is an important mediator of the inflammatory response. MRL-
Ipr/lpr mice overexpress N0S2 and overproduce nitric oxide, parallel with the 
development of autoimmune syndrome with a variety of inflammatory manifestations. 
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Previous studies have shown that nitric oxide production with nonselective NOS 
inhibitor N*^ - monomethyl arginine is shown to reduce glomerulonephritis, arthritis 
and vasculitis. 
Nitric oxide production is increased in patient with SLE and two potential 
sources of excessive nitric oxide are activated endothelial cells and keratinocytes via 
up regulated N0S2 (Belmont et al, 1997). Serum nitrite level which is an index of 
nitric oxide production, was found to be correlated with the disease activity and with 
the levels of antibodies to dsDNA (Wigand et al, 1997; Ho et al, 2003; Wong et al, 
2002). Serum N°- hydroxyl-L- arginine seems to be a more specific and reliable index 
of an increased activity of this enzyme in patients with acute or chronic inflammatory 
disease than nitrate, and is the major circulating metabolite of nitric oxide whose 
concentration is influenced by dietary intake. The significance of oxidative stress, 
nitric oxide and antioxidants in SLE has also been reported (Mohan and Das, 1997). 
Eicosapentanoic acid and docosahexanoic acid (essential fatty acids) can modulate 
oxidative stress and nitric oxide synthesis and may have a regulatory role in the 
synthesis of antioxidant enzymes, such as superoxide dismutase and glutathione 
peroxidase. They have also suggested that measurement of lipid peroxides, nitric 
oxide and anti-oxidants can be used as markers to predict prognosis in patients with 
SLE. 
Approach to therapy 
Despite the power of modem molecular approaches and persisting 
investigative efforts, lupus remains an enigmatic disorder. Corticosteroids and 
cyclophosphamides are widely used for the treatment of SLE, which exert 
immunosuppressive activities (Kromemer and Martinez, 1994). However, their utility 
is restricted by their undesirable side effects including infection, premature 
cardiovascular mortality, infertility and neoplasia (Hellmann et al, 1987; Pistiner, 
1991). Immunosuppressive drugs with a high desired/adverse reaction ratio are 
awaited. It has been shown that FTY720 [2-amino-2-(z-{4-octyl-phenyl} ethyl)-1,3-
propane-diol hydrochloride], a novel immunosuppressant is efficacious for the 
treatment of experimental SLE in MRL/lpr mice (Okazaki et al, 2002). 
If lupus is due to a loss of self-tolerance, it may be possible to design a more 
general therapy to restore self tolerance (Steinberg, 1994). Gene therapy, another 
approach to curing of lupus has been performed successfully in mice. Provided that 
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kidneys are not yet irreversibly damaged, the use of human soluble or chimeric 
receptors (constant part of human IgG heavy chain linked to the human soluble IFN-
receptor) (Kurschner et al, 1992 a,b) is an attractive prospective in the treatment of 
autoimmune glomerulonephritis in human SLE (02men et a/., 1995). Specific 
immunotherapy for human SLE can be designed (Datta et al, 1997b). Once the 
pathogenic Th cell epitopes in the nucleosomes are identified, autoantigen mediated 
signal 1 to the Th cells could be blocked, in combination with anti-CD40-L therapy to 
block CD40-mediated signal 2 to the pathogenic autoantibody producing B cells. 
Thus instead of blocking signals 1 and 2 for either the autoimmune T or the 
autoimmune B cell, both of these major players in the pathogenic unit could be 
blocked by combination therapy. 
Objectives of the present study 
Nitric oxide is a multifaceted molecule having a half life of 2-30 sees. 
Reaction of nitric oxide with superoxide in biological media yields peroxynitrite, 
which is a potent oxidant. Nitric oxide mediates DNA damage by various 
mechanisms. It has been reported that NO production is increased in patients with 
systemic lupus erythematosus. The role of nitric oxide in apoptosis and auto-immune 
diseases has also been indicated. The circulating antibodies in SLE patients have 
found to be polyspecific with respect to antigen binding characteristics as they 
recognize variety of nucleic acids, also bind cardiolipin, chondroitin sulphate, 
vimentin and a host of other cellular proteins. In the present studies the possible role 
of NO in the induction of autoantibodies in SLE has been investigated. Recent studies 
have implicated nucleosome core particles in the induction of circulating human 
autoantibodies in systemic autoimmunity (Gabler et al, 2003). 
In the present study, chromatin was isolated from goat liver. It was modified 
with nitric oxide, which was generated by the reduction of sodium nitrite with sodium 
dithionite. The effect of NO on chromatin and the modification in DNA and protein 
moieties was characterized by UV and fluorescence spectroscopy, thermal 
denaturation studies, circular dichroism, identification of base modification and 
nuclease S1 digestibility. 
The well-characterized NO-modified chromatin and its native form were used 
as an immunogen for the induction of antibodies in rabbits. The NO-modified 
chromatin was found to be highly immunogenic as compared to the native chromatin. 
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The specificity of induced antibodies was ev^uated by competition ELISA and gel 
retardation assay. In order to assess the possible role of modified epitopes of 
chromatin in the etiology of autoimmune diseases such as SLE, sera from SLE 
patients were investigated for the presence of antibodies to native and modified 
chromatin. 
C^xpenwievita 
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MATERIALS 
Calf thymus DNA, nuclease SI, bovine serum albumin, anti-human/anti-rabbit 
IgG-alkaline phosphatase conjugates, p-nitrophenyl phosphate, ethidium bromide, 
Coomassie Brilliant Blue G-20 and R-250, sodiimi dodecyl sulphate, Tween-20, 
Triton X-100, Millipore filter (0.45 |xm pore size), Freund's complete and incomplete 
adjuvants, polydeoxyribonucleotides, and agarose were purchased from Sigma 
Chemical Company, U.S.A. Synthetic polynucleotides ,DEAE Sephadex A-25, Ficoll 
400, xylene cyanole FF were purchased fi-om Pharmacia Fine Chemicals, Sweden. 
Folin-Ciocalteau reagent and Blue Dextran 2000 were purchased fi-om Centre for 
Biochemical Technology, New Delhi. Protein A Sepharose CL 4B was from Genei, 
India. Absolute ethanol was obtained from BDH Laboratory Supplies, England. 
Polystyrene microtitre flat bottom ELISA plates having 96 wells (7 mm 
diameter) were purchased from NUNC, Denmark. Acrylamide, ammonium 
persulphate, bisacrylamide, N,N,N,N tetramethylethylenediamine (TEMED) were 
form Bio-Rad Laboratory U.S.A. EDTA (disodium salt), sodium nitrite,uric acid, 
mannitol, ascorbic acid carboxy PTIO, isoamyl alcohol, methanol, glacial acetic acid 
were from Qualigens, India. Sodium dithionite was from S.D. Fine chemicals, India. 
Diphenylamine was chemically pure. All other reagents/chemicals were of the highest 
analytical grade available. 
Equipment 
Shimadzu UV-240 spectrophotometer equipped with thermo-programmer and 
controller unit, high speed tissue homogenizer (York Scientific Industries, Delhi), 
ELISA microplate reader MR-600 (Dynatech, U.S.A.), ELICO pH meter model Ll-
120, ultraviolet lamp (Vilber Lourmat, France), JASCO J-710 spectropolarimeter, 
UV-transilluminator (Vilber Lourmat, France), agarose gel electrophoresis assembly 
(GNA-100) and gradient mixer GM-1 (Pharmacia, Sweden), Avanti 30 table top high 
speed refrigerated centrifuge (Beckman, U.S.A.), polyacrylamide gel electrophoresis 
assembly (Bio-Rad, U.S.A.), Fluorimeter (Hitachi, Japan) were the major equipments 
used in this study. 
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Collection of sera and blood samples 
Six to seven serum samples from normal healthy subjects, male and female 
were collected. Each sample was identified, screened for any abnormality present 
from standard blood testing procedures and collected together to form normal human 
serum pool. SLE sera were obtained from outdoor and indoor patients of the 
Department of Medicine, All India Institute of Medical Sciences, New Delhi. The 
SLE sera showed high titre anti-DNA antibodies and fiilfilled the American College 
of Rheumatology revised criteria for the classification of SLE (Amett et ah, 1988). 
Sera samples were decomplemented at 56°C fro 30 min and stored in aliquots at 
-20 °C with 0.1% sodium azide as preservative. 
METHODS 
Determination of DNA concentration 
DNA concentration was estimated colorimetrically by the method of Burton 
(1956) using diphenylamine reagent. 
(a) Crystallization of diphenylamine 
Diphenylamine (2g) was dissolved in 200 ml boiling hexane. After adding 0.5 
g of activated charcoal, the hot mixture was filtered through Whatman No. 1 
filter paper and the filtrate was kept overnight at 4 °C and dried at room 
temperature before use. 
(b) Preparation of diphenylamine reagent 
750 mg of recrystallized diphenylamine was mixed with 50 ml of glacial 
acetic acid and 0.75 ml concentrated sulphuric acid. The reagent was prepared 
fresh before use. 
(c) Procedure 
One ml of DNA sample was mixed with 1.0 ml of IN perchloric acid and 
incubated at 70 °C for 15 min. One hundred \iL of 5.43 mM acetaldehyde was 
added followed by 2.0 ml of freshly prepared diphenylamine reagent. The 
contents were mixed and incubated at room temperature for 16-20 hrs. 
Absorbance was read at 600 nm and the concentration of DNA in unknown 
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samples was determined from a standard plot of calf thymus DNA purified 
free of RNA and proteins. 
Determination of protein concentration 
Protein was estimated by the methods of Lowry et al. (1951) and Bradford 
(1976). 
Protein estimation by Folin 's-phenol reagent 
The protein estimation by this method utilizes alkali (to keep the pH high), 
ions (to chelate proteins) and tartarate (to keep the Cu^ * ions in solution at high 
pH). 
(a) Folin-Ciocalteau reagent 
The reagent was purchased from Centre for Biochemical Technology, New 
Delhi and diluted 1:4 with distilled water before use. 
(b) Alkaline copper reagent 
The components of alkaline copper reagent were prepared as follows: 
(i) Two percent sodium carbonate in 100 mM sodium hydroxide. 
(ii) 0.5 percent copper sulphate in 1 percent sodium potassium tartarate. 
The working reagent was prepared fresh before use by mixing 
components (i) and (ii) in the ratio of 50:1. 
(c) Procedure 
To one ml of protein sample was added 5 ml of alkaline copper reagent and 
incubated for 10 min at room temperature. One ml of working Folin-
Ciocalteau reagent was added and the tubes were read at 660 nm after 30 min. 
The concentration of protein in unknown sample was determined from a 
standard plot of bovine serum albumin. 
Protein estimation by dye-binding method 
This assay is based on color change when Coomassie Brilliant Blue G 250 in 
acidic medium, binds strongly to protein hydrophobically and at positively charged 
groups (Bradford, 1976). In the environment of these positively charged groups, 
protonation is suppressed and a blue color is observed (A,max-595 nm). 
37 
(a) Dye preparation 
One hundred mg Coomassie Brilliant Blue G-250 was dissolved in 50 ml of 
95% ethanol and 100 ml of 85% (v/v) orthophosphoric acid was added. The 
resulting solution was diluted to a final volume of one litre and filtered 
through Whatman No. 1 filter paper to remove undissolved particles. 
(b) Protein assay 
To one ml of solutions containing 10-100 \ig protein, 5 ml of dye solution was 
added and contents mixed by vortexing. The absorbance was read at 595 nm 
after 5 min against a reagent blank. 
Purification of calf thymus DNA 
Commercially obtained calf thymus DNA was purified free of proteins and 
single stranded regions as described by Ali et al. (1985). DNA (2 mg/ml) was 
dissolved in 0.1 X SSC buffer (15 mM sodium citrate and 150 mM sodium chloride, 
pH 7.3) and extracted with an equal volume of chloroform isoamyl alcohol (24:1) in a 
stoppered container for 1 hr. The aqueous layer containing DNA was separated from 
the organic layer was re-extracted with chloroform-isoamyl alcohol. The DNA was 
precipitated with two volumes of cold absolute ethanol and collected on a glass rod. 
After drying in air, the DNA was dissolved in acetate buffer (30 mM sodium acetate 
containing 30 mM zine chloride, pH 5.0) and treated with nuclease SI (150 units/mg 
DNA) at 37°C for 30 min to remove single stranded regions. The reaction was 
stopped by adding one-tenth volume of 200 mM EDTA, pH 8.0. The nuclease SI 
treated DNA was extracted twice with chloroform-isoamyl alcohol and finally 
precipitated with two volumes of cold ethanol. The precipitate was dissolved in 
phosphate-buffered saline (PBS) (10 mM sodium phosphate containing 150 mM 
sodium chloride), pH 7.4. 
Polyacrylamide gel electrophoresis (PAGE) for proteins 
PAGE was performed as described by Laemmli (1970). 
(i) Acrylamide-bisacrylamide (30:0.8) 
A stock solution was prepared by dissolving 30 gm of acrylamide and 0.8 gm 
bisacrylamide in distilled water to a final volume of 100 ml. 
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(ii) Resolving gel buffer 
A stock solution of Tris (3 M) was prepared by dissolving 36.3 gm Tris base 
in 48.0 ml of IN HCl. The contents were mixed, pH adjusted to 8.8 and the 
final volume brought to 100 ml with distilled water. 
(Hi) Stacking gel buffer 
6.05 gm Tris was dissolved in 40 ml distilled water, pH titrated to 6.8 with IN 
HCl and the final volume adjusted to 100 ml with distilled water. 
(iv) Electrode buffer 
3.03 gm Tris, 14.4 gm glycine and 1.0 gm SDS were dissolved in distilled 
water, pH adjusted to 8.3 and final volume made up to one litre. 
(v) Procedure 
Glass plates, separated by 1.5 mm thick spacer were sealed with 1% agarose. 
The resolving gel mixture was prepared by mixing the components in the 
appropriate volume and poured into the space between the glass plates leaving 
sufficient space at the top for the stacking gel. After the polymerization of 
separating gel, stacking gel mixture was poured and allowed to solidify. 
Protein samples containing 10% glycerol and 0.002% bromophenol blue were 
applied and electrophoresis was carried out at 60V for 6-8 hrs. Staining of the 
gel was achieved with 0.1% Coomassie Brilliant Blue R 250 (in 25% 
isopropanol and 10% glacial acetic acid). Destaining was carried out in a 
mixture of 10% acetic acid and 10% methanol. 
Recipe for 7.5% SDS-PAGE with 2.5% stacking gel 
Solutions Stacking gel Resolving gel 
Acrylamide-bisacrylamide 
Stacking gel buffer 
Resolving gel buffer 
Distilled water 
10% SDS 
1.5% Ammonium persulphate 
TEMED 
1.25 ml 
2.5 ml 
-
5.65 ml 
0.1ml 
0.5 ml 
0.75 ^ 1 
7.5 ml 
-
3.75 ml 
16.95 ml 
0.3 ml 
1.5 ml 
15^1 
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PAGE for DNA 
Nucleic acid samples were subjected to PAGE under non-denaturing 
conditions as described by Laemmli (1970). 
(a) Buffers used 
(i) Electrode buffer 
The electrophoretic buffer used was TAE, pH 7.9 (40 mM Tris, 1.14 ml 
glacial acetic acid and 1 mM EDTA). Final volume adjusted to one litre. 
(ii) Procedure 
The PAGE assembly was set up and the glass plates separated by 1.5 mm 
thick spacer were sealed with 1% agarose from the sides and bottom. The non-
denaturing gel was prepared and poured between the glass plates and allowed 
to polymerize at room temperature. Nucleic acid samples were mixed with 
one-tenth volume of 'stop mix' (30% Ficoll, 0.025% xylene cyanole FF and 
500 mM EDTA in 10 times concentrated TAE buffer) and applied onto the 
gel. The gel was electrophoresed for 8-10 hr at room temperature at 80 Volts, 
stained with ethidium bromide (0.5 |ag/ml) and visualized under UV light. 
Recipe for 7.5% non-denaturing PAGE 
Solution Volume 
Acrylamide-bisacrylamide 10.0 ml 
1.5% Ammonium persulphate 1.5 ml 
Distilled water 23.5 ml 
TEMED 20.0 i^l 
Isolation of chromatin 
Chromatin was isolated as descried by Bonner et al. (1968) with slight 
modifications. Ten g of fresh goat liver was homogenized with 200 ml of saline 
EDTA (0.075 M NaCl, and 0.024 M EDTA, pH 8.0). The homogenate was strained 
through 6-8 layers of cheese cloth. The filtrate was centrifuged at 1500 g for 15 
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minutes. The pellet was homogenized in 40 ml of Tris buffer, sedimented at 10,000 g 
for 15 minutes. This step was repeated once. The fmal pellet was suspended in 30 ml 
of Tris buffer (0.05 M, pH 8.0). Five ml aliquots of the above suspension were 
layered on 25 ml portions of 1.7 M sucrose (0.01 M Tris buffer, pH 8.0) contained in 
centrifuge tubes. The upper two-third of each tube was gently mixed and the tubes 
were then centrifiiged at 21,000 rpm for 3 hours in the Spinco SW 25 head (rotor 
temperature 4°C). The pellets were resuspended in 0.01 M Tris buffer, pH 8.0, and 
dialyzed against the same buffer overnight. The dialyzed suspension was sheared in 
Virtis homogenizer for 90 seconds, stirred for 30 minutes, and then centrifiiged at 
10,000 g for 30 minutes. The supernatant was taken out and UV spectra of the diluted 
supernatant was recorded. The supernatant obtained is referred to as sheared liver 
chromatin. 
Modification of chromatin by nitric oxide 
Isolated chromatin was modified with nitric oxide generated by the reduction 
of sodium nitrite with sodium dithionite as described by Sugiura and Matsumoto 
(1995). A total volume of 3.0 ml of reaction mixture contained chromatin (A260 =2), 
20 mM Tris-HCl buffer, pH 7.5, sodium nitrite (3 mM) and sodium dithionite (300 
mM). The reaction mixture was kept for 3 hours. Extensive dialysis of the sample was 
done immediately at the end of incubation time to remove the salts. Native chromatin 
incubated with 3 mM sodium nitrite or 300 mM sodium dithionite alone served as 
controls. 
Spectroscopic analysis 
The ultraviolet spectra of modified and unmodified chromatin samples were 
recorded in the wavelength range of 210-400 nm on a Shimadzu lJV-240 
spectrophotometer. The modifications incurred on native chromatin were also 
analyzed by UV-difference spectroscopy. 
Fluorescence emission spectroscopy of native and modified chromatin 
samples using ethidium bromide at excitation wavelength of 260 nm was performed. 
Along with this, fluorescence emission spectroscopy of native and modified 
chromatin samples at excitation wavelength of 280 nm was recorded. 
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Absorption-temperature scan 
Thermal denaturation analysis of chromatin was performed in order to 
ascertain the degree of modification incurred on the chromatin by determining mid 
point melting temperatvire (Tm). Native and modified chromatin samples were 
subjected to heat denaturation on a Shimadzu UV-240 spectrophotometer coupled 
with a temperature programmer and controller assembly (Hasan and Ali, 1990). All 
the samples were melted from 30°C to 95°C at a rate of 1.5°C / min after 10 min 
equilibration at 30°C. The change in absorbance at 260 nm and 280 nm separately was 
recorded with increasing temperature. Percent denaturation was calculated as follows: 
Percent denaturation 
A T - A30 
A30 
xlOO 
Where, AT 
A30 
Absorbance at a temperature T C 
Final maximum absorbance on the 
completion of denaturation 
Initial absorbance at 30°C 
Nuclease SI digestibility 
Native and modified chiomatin were characterized by nuclease SI digestibility 
(Matsuo and Ross, 1987). One microgram each of native and modified chromatin in 
acetate buffer (30 mM each of sodium acetate and zinc chloride, pH 5.0) were treated 
with nuclease SI (20 units/^g DNA) for 30 min at 37°C. The reaction was stopped by 
adding one tenth volume of 200 mM EDTA, pH 8.0. The digested and control 
samples were subjected to agarose gel electrophoresis. 
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(i) Gel preparation 
Agarose (1%) in TAE buffer (40 mM Tris-acetate, pH 8.0 containing 2 mM 
EDTA) was dissolved by heating. The solution was cooled to about 50°C and then 
poured into gel tray and allowed to solidify at room temperature. 
(ii) Sample preparation and loading 
Native and modified chromatin samples treated with nuclease SI were mixed 
with one-tenth volume of sample buffer (0.125% bromophenol blue, 30% FicoU 400, 
500mM EDTA in lOX electrophoresis buffer). The samples were loaded in the wells 
and electrophoresed for 2 hr at 30mA. The gels were stained with ethidium bromide 
(0.5 ng/ml), viewed by illumination imder UV light and photographed. 
Circular dichroism measurements 
Circular dichroism (CD) measurements of native and nitric oxide modified 
chromatin in 0.01 M Tris, pH 8 were performed in 10 mm path length cells at a 
constant temperature of 4 °C. Freshly isolated goat liver chromatin samples were 
used. There were two wavelength ranges chosen. One from 200 nm - 250 nm and 
other from 250 nm - 300 nm. The concentration of chromatin was adjusted between 
A260 - 1 and 1.7 O.D. A scan of buffer alone was recorded to adjust the baseline. CD 
data was collected at 2.5 nm intervals. Molar ellipticity [9] as [(deg cm )/dmol] was 
calculated by the equation 
[0] = (M/10cl)e 
where, [9] is the molar ellipticity, M is the average molecular weight of a nucleotide 
or amino acid residue, c is the concentration of DNA or protein in g/ml, 1 is the path 
length of the cell in centimeters, and 9 is the measured ellipticity of the sample. M is 
309 for DNA and 115 for protein. 
Separation and quantitation of DNA bases 
The separation and quantitation of bases in modified and unmodified DNA 
extracted from chromatin was done according to the method described by Hasan and 
Ali (1990). 
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(a) Acid hydrolysis ofDNA samples 
Native and NO-modified DNA was extracted from respective chromatin 
samples by taking equal volume of chromatin and chloroform-isoamyl alcohol (24:1) 
in a stoppered container for 1 hr. The aqueous layer containing DNA was separated 
from the organic layer and re-extracted with chloroform-isoamyl alcohol. Dialysis in 
1 mM Tris, pH 7.6 was done to remove impurities. Purity of DNA in samples was 
calculated from the ratio A26o/A28o- Further, DNA samples were precipitated with two 
volumes of cold ethanol and dissolved in 70% perchloric acid. The samples were 
heated at 100°C for 1 hr to release the bases. The hydrolyzate was neutralized and 
chromatographed on DEAE Sephadex A-25 matrix. 
(b) DEAE Sephadex A-25 column chromatography 
The swollen ion exchanger was suspended in the equilibrating buffer (1 mM 
Tris-HCl, pH 7.6) and poured in a column. The column was extensively equibilibrated 
and 3 ml of sample was applied and eluted v^th a linear gradient of 1-20 mM Tris-
HCl, pH 7.6 at a flow rate of 40 ml/hr. Fractions of 3 ml were collected and 
absorbance recorded at 260 nm. Elution profiles of individual bases and hydrolyzed 
native DNA served as standards. 
Immunization schedule 
Female rabbits (8-12 months, weight 1-1.5 kg) were used for immunization. 
Native and modified chromatin (50 i^g) were emulsified with an equal volume of 
complete Freund's adjuvant and injected intramuscularly in female rabbits (Hasan et 
al, 1991). Subsequent injections were given in incomplete Freund's adjuvant. Each 
animal received a total of 300 \xg of antigen in the course of 6 injections. Blood was 
collected from marginal vein of the ear. Serum was separated and decomplemented by 
heating at 56°C for 30 minutes. Pre-immune serum was collected prior to 
immunization. The sera were stored in small aliquots at - 20°C with 0.1% sodium 
azide as preservative. 
Isolation of IgG by Protein-A agarose 
Serum IgG was isolated by affinity chromatography on Protein-A agarose 
column. Serum (0.3 ml) diluted with equal volume of PBS, pH 7.4 was applied to 
column (12 mmX45 mm) equilibrated with the same buffer. The wash through was 
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recycled 2-3 times. Unbound IgG was removed by extensive washing with PBS, pH 
7.4. The bound IgG was eluted with 0.58% acetic acid in 0.85% sodium chloride 
(Coding, 1976) and neutralized with 1 ml of IM Tris-HCl, pH 8.5. Three ml fractions 
were collected and read at 251 and 278 run. The IgG concentration was determined 
considering 1.40 OD280 = 1.0 mg IgG/ml. The isolated IgG was dialyzed against PBS, 
pH 7.4 and stored at -20 "'C with 0.1% sodium azide. 
Immunological detection of antibodies 
Sera were tested for antibodies by enzyme linked immunosorbent assay and 
gel retardation assay. 
(a) Enzyme linked immunosorbent assay 
ELISA was performed using polystyrene (96 well) flat bottom microtitre 
plates as described by Aotsuka et al, 1976. The following reagents were 
prepared in distilled water and used in enzyme immunoassay. 
(!) Buffers and reagents 
Tris buffered saline (TBS) 
10 mM Tris, 150 mM NaCl, pH 7.4 
Tris buffered saline-Tween 20 (TBS-T) 
20 mM Tris, 144 mM NaCl, 2.68 mM KCl, pH 7.4 containing 500 t^l Tween 
20/L 
Carbonate-bicarbonate buffer 
15 mM sodium carbonate, 35 mM sodium bicarbonate, pH 9.6, containng 2 
mM magnesium chloride. 
Citrate-phosphate buffer 
50 mM citric acid, 50 mM Na2HP04, pH 5.0. 
Substrate 
500 |ig of p-nitrophenyl phosphare (p-NPP)/ml in carbonate-bicarbonate 
buffer. 
(ii) Procedure 
Antibodies were detected by ELISA using polystyrene microtitre plates as 
solid support. One hundred microlitre of 2.5 mg/ml antigen in TBS, pH 7.4 was 
coated in test wells of microtitre plates, incubated for 2 hr at 37°C and overnight at 
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4°C. The antigen coated wells were washed three times with TBS-T to remove 
unbound antigen. Unoccupied sites were blocked with 150 fil of 1.5% BSA in TBS 
for 4-5 hrs at room temperature. The plates were washed once with TBS-T and 
antibody (100 i^l/well) to be tested, were diluted in TBS and added to each well. After 
2 hr incubation at 37°C and overnight at 4°C, the plates were washed four times with 
TBS-T and an appropriate anti-immunoglobulin alkaline phosphatase conjugate was 
added to each well. After incubation at 37°C for 2 hr, the plates were washed four 
times with TBS-T and three times with distilled water and developed using p-
nitrophenyl phosphate substrate. The absorbance was recorded at 410 nm on an 
automatic microplate reader. Each sample was run in duplicate. The control wells 
were treated similarly but were devoid of antigen. Results were expressed as a mean 
01 A test "" Acontrol-
(b) Competition ELISA 
The antigenic specificity of the antibodies was determined by competition 
ELISA (Hasan et al, 1991). Varying amounts of inhibitors (0-20 fig/ml) were mixed 
with a constant amount of antiserum or IgG. The mixture was incubated at room 
temperature for 2 hr and overnight at 4°C. The immime complex thus formed was 
coated in the wells instead of the serum. The remaining steps were the same as in 
direct binding ELISA. Percent inhibition was calculated using the formula. 
^inhibited 
Percent inhibition = 1 x 100 
•^uninhibited 
(c) Band shift assay 
For the visual detection of antigen antibody binding and immune complex 
formation, gel retardation assay was performed (Sanford et al., 1988). A 
constant amount of antigen (native and modified chromatin) was incubated 
with varying amounts of IgG in PBS, pH 7.4 for 2 hr at 37°C. One-tenth 
volume of 'stop mix' dye was added to the mixture and electrophoresed on 1% 
agarose for 2 hr at 30 mA in TAE buffer, pH 7.9. The gels were stained with 
ethidium bromide (0.5 mg/ml), visualized under UV light and photographed. 
eduild 
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UV absorption spectrum of isolated chromatin 
The isolated goat liver chromatin exhibited major peak at 260 nm and showed 
negligible absorbance at around 320 nm (Fig. 4). A258/A280 ratio was 1.63 and 
A258/A320 was around 9. 
Gel electrophoresis pattern of chromatin 
Agarose gel electrophoresis of isolated chromatin on 1% gel. The purified 
chromatin showed a single homogenous electrophoretic band (Fig 5). 
Modification of chromatin by nitric oxide 
Isolated chromatin was modified with nitric oxide generated by the reduction 
of sodium nitrite with sodium dithionite by the method of Sugiura and Matsumoto 
(1995). A total volume of 3.0 ml of reaction mixture contained chromatin A260 = 2, 
20 mM Tris-HCl buffer, pH 7.5, sodium nitrite (3 mM) and sodium dithionite 
(300 mM). The reaction mixture was kept for 3 hr followed by extensive dialysis to 
remove salts. Native chromatin incubated with either of the salts under same reaction 
conditions served as controls. 
Polyacrylamide gel electrophoresis of chromatin 
PAGE of isolated chromatin along with chromatin modified with nitric oxide 
produced at different salt concentrations was performed on 7.5% resolving gel (Fig. 
6). With increasing concentration of nitric oxide generated by varying concentration 
of salts, a more compact chromatin band was observed. Increasing salt concentration 
increased nitric oxide production. 
Chromatin damage was maximally achieved at 3:300 mM salt concentration. 
However, increasing salt concentration fiirther, didn't showed any fiuther damage as 
perceived fi-om spectral studies (data not shown). Thus, 3:300 mM salt concentration 
was taken as standard for chromatin modification and this was used for further 
studies. 
Agarose gel electrophoresis of native and modified chromatin 
Agarose gel electrophoresis of native and NO-chromatin was performed on 
1% gel (Fig.7). Single homogenous bands were observed, though there was more 
stretching seen in case of modified chromatin as compared to its native form. 
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Fig. 4. UV absorption spectrum of liver chromatin. 
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Fig. 5 Agarose gel electrophoresis pattern of chromatin 
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Fig. 6 Polyacrylamide gel electrophoresis of native and NO-chromatin. Lane 1 
contained native chromatin. Lane 2 to 4 contained NO-chromatin modified 
with 1:100, 2:200 and 3:300 mM salt concentrations, respectively. Sodium 
nitrite and sodium dithionite were the salts used. 
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Fig. 7 Agarose gel electrophoretic pattern of native cliromatin (lane 1) and NO-
chromatin (lane 2). The agarose gel was run at 30 mA for 1 hr. 
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Ultraviolet absorption spectral studies 
The UV absorption spectra of NO-modified chromatin showed loss of peak 
sharpness and showed hyperchromicity (51%) at 260 nm (Fig. 8). The modifications 
incurred on chromatin were also analyzed by UV-difference spectroscopy (Fig. 8, 
inset). The spectral curve exhibited increased absorbance at 240 rmi. 
Chromatin was modified with nitric oxide in the presence of various 
quenchers (Fig. 9). Generation of nitric oxide was confirmed using specific quencher 
such as carboxy PTIO, percent modification of chromatin was 14% only. While in the 
presence of ascorbic acid and uric acid, percent modification of chromatin was 18% 
and 44%, respectively. While percent modification of chromatin by nitric oxide in the 
presence of maimitol was 98%, which is a specific quencher for reactive oxygen 
species (ROS). 
Further, chromatin was modified in the absence and presence of carboxy PTIO 
a specific quencher of nitric oxide. Figure 10 shows UV absorption spectra of native 
chromatin, NO-chromatin and NO-chromatin in the presence of carboxy PTIO at 
different concentrations of 10 mM and 110 mM. In the absence of carboxy PTIO 
there was marked hyperchromicity whereas hyperchromicity decreased with increased 
concentration of carboxy PTIO, hyperchromicity decreased 4% at 10 mM and 31% at 
110 mM concentration of carboxy PTIO, respectively. 
Fluorescence spectroscopy 
Fluorescence emission spectra of native and NO-chromatin was taken at two 
different excitation wavelengths, 260 nm and 280 nm. Excitation at 260 nm using 
ethidium bromide in the sample is shown in Figure 11. There was marked decrease in 
the fluorescence intensity of modified chromatin as compared to native chromatin. 
Alteration in the structure of chromatin and generation of DNA strand breaks due to 
modification by nitric oxide may be responsible for decreased fluorescence intensity. 
Emission spectra of native and NO-chromatin at excitation wavelength of 
280 nm also indicated marked increase in the fluorescence intensity of NO-chromatin 
as compared to native chromatin (Fig. 12). This may be due to the exposure of 
chromophoric groups and/or unfolding of proteins in chromatin leading to overall 
structural alterations occurring due to radical modification. 
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Fig. 8 UV absorption spectra of native ( ) and NO-chromatin ( ) Inset: 
UV difference spectra of NO-chromatin ( •)• Native chromatin served as 
control. 
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QUENCHERS 
Fig. 9 Quenching of nitric oxide production in the presence of different 
quenchers. NO-chromatin (1); modification in presence of mannitol (2); 
uric acid (3); ascorbic acid (4) and carboxy PTIO (5). 
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Fig. 10 UV absorption spectra of chromatin modified in absence and presence of 
two different concentrations of carboxy PTIO, a specific quencher of NO. 
Native chromatin (a), NO-chromatin (d), NO-chromatin with 10 mM 
carboxy PTIO (c) and NO-chromatin with 110 mM carboxy PTIO (b). 
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Fig. 11 Fluorescence emission spectra of native ( ) and NO-modified 
chromatin ( ). Excitation wavelength was 260 nm. 
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chromatin ( ). Excitation wavelength was 280 nm. 
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Thermal denaturation of native and modified chromatin 
Thermally induced transitions were measured spectrophotometrically at 
260 nm and 280 nm by heating samples at a rate of 1.5 °C per min. Melting curves 
were recorded at temperatures from 30 °C to 95 °C. Figure 13 show thermal 
denaturation profile of native and NO-modified chromatin at 260 nm. Increase in 
absorption at 260 nm was taken as a measure of denaturation. The melting 
temperature of native chromatin at which 50% of the structural organization is lost 
was fovmd to be 81°C, while in case of NO-modified chromatin it was found to be 
72 °C, a net decrease of 9 °C in the Tm value of modified chromatin was observed 
when compared to its unmodified native conformer. These findings indicate that the 
decrease in Tm is primarily due to DNA strand breaks and structural alterations of 
chromatin. Thermal denaturation characteristics of native and modified chromatin at 
260 nm is summarized in Table 6. 
Figure 14 show Tm profile of native and NO-modified chromatin taken at 280 
nm. Decrease in absorption at 280 nm was taken as a measure of denaturation. In case 
of native chromatin a decrease in absorbance till 55 °C was found. On further 
increasing the temperature a constant increase in absorbance was observed. While in 
case of NO-modified chromatin decrease in absorbance was seen from 30 °C to 86 "C 
after which absorbance kept on increasing. The melting temperature of native 
chromatin at which 50% of structural organization is lost was found to be 36 °C while 
that of NO-modified chromatin was 60°C. Thus increase in the Tm value of modified 
sample as compared to its native counterpart, suggest protein-protein or protein-DNA 
adduct formation due to nitric oxide exposure. 
Nuclease SI digestibility of native and modified chromatin 
Native and modified chromatin were digested with nuclease SI (20 units/jig 
chromatin) for 30 min at 37 °C, undigested chromatin sample served as control. 
Samples were run on 1% agarose gel. Figure 15 shows nuclease SI digestibility of 
native and NO-chromatin. The result showed substantially decreased intensity in case 
of NO-modified sample. However, the intensity loss in case of immodified chromatin 
was substantially less as compared to modified sample. 
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Fig. 13 Thermal denaturation profile of native (o) and NO-' 
260 nm. chromatin (•) at 
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Table 6 
Thermal denaturation characteristics of native and NO-chromatin 
Parameter Native chromatin NO-chromatin 
Percent hyperchromacity at 36 14 
95°C 
Melting temperature (Trnj^ C) 81 72 
Onset of melting °C 50 35 
60 
105 
Temperature ( C) 
Fig. 14 Thermal dcnaturation profile of native (o) and NO-chromatin (•) at 
280 nm. 
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Fig. 15 Nuclease SI digestibility of native and NO-chromatin. Lane 1 contained 
native chromatin, while lane 2 contained native chromatin treated with 
nuclease SI. Lane 3 contained NO-chromatin, while lane 4 contained NO-
chromatin treated with nuclease SI for 30 min. Electrophoresis was carried 
out on 1% agarose gel for 2 hr at 30 mA. 
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Circular dichroism of native and modified chromatin 
The circular dichroic spectra of the native and nitric oxide modified chromatin 
is shown in Figure 16. The study was carried out at two different wavelengths (a) 
wavelength range 200 mn-250 nm, the CD of chromatin in this region is largely due 
to peptide/protein chromophores (Hjelm et al, 1975). (b) wavelength range 
250 iun-300 lun, the CD of chromatin in this region is mainly due to DNA and is 
different from that of DNA in free solution. (Hjelm et al, 1975). 
In this study, native chromatin showed a negative peak at 208 run and another 
at 223 nm (Fig. 16,a). Nitric oxide modified chromatin compared to native chromatin 
showed shifting of negative peak at 217 run from 208 nm, with change in ellipticity 
from -10.8 mdeg to -10.0 mdeg and retained its 223 rmi peak with change in ellipticity 
from -10,0 mdeg to -9 mdeg with appearance of shoulder around 230 nm (-8.0 mdeg). 
While in Figure 16 (b), native chromatin showed a shoulder at 283 imi (+4.0 mdeg) 
and NO-chromatin compared with native chromatin showed decrease in ellipticity 
from +4.0 mdeg to +2.0 mdeg at 283 nm. 
Modification of nitrogenous bases 
In order to separate and quantify the modification of bases, NO-chromatin 
solution was treated with chloroform-isoamyl alcohol to extract DNA, which was then 
subjected to acid hydrolysis. The neutralized hydrolyzate was applied to a DEAE 
Sephadex A-25 column and eluted with a linear gradient of 1-20 mM Tris-HCl buffer, 
pH 7.6. The elution profile of individual standard bases is shown in Figure 17. The 
elution profile of acid hydrolyzed native calf thymus DNA run as standard was 
similar to that obtained v^th individual bases (Fig. 18). 
Figure 19 shows the elution profile of acid hydrolyzate of DNA extracted from 
chromatin. The peaks obtained were identified by comparing with the 
chromatographic pattern of the standard plot for native calf thymus DNA (Fig. 18). 
The peaks obtained for individual bases of DNA from native chromatin matched with 
the peaks of the standard plot. Figure 20 shows the elution profile of acid hydrolyzate 
of DNA exfracted from NO-chromatin. The peaks obtained were identified with the 
chromatographic pattern of DNA from native chromatin. The first and second peak 
represent modified and unmodified cytosine, while the third and fourth peak represent 
modified and unmodified thymine. Adenine also eluted as two peaks (numbers 5 and 
6) as also guanine (number 7 and 8), representing the modified and unmodified base. 
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Fig. 16 Circular dichroic spectra of native ( ) and NO-chromatin ( ). (a) 
wavelength range for protein residues <250 nm (b) wavelength range 
chosen for DNA bases >250 nm. 
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The extent of modification of bases by nitric oxide was determined by measuring the 
peak areas of the modified and the corresponding unmodified bases. Among the bases 
modified, guanine was modified to a maximum extent of 46%, while cytosine, 
adenine and thymine were modified to the extent of 25%, 14% and 7%, respectively 
(Table 7). 
Immunogenicity of nitric oxide modified chromatin 
The antigenicity of native chromatin and nitric oxide modified chromatin was 
probed by inducing antibodies in rabbits. The antigenic specificity of the induced 
antibodies was assayed by direct binding and competition ELISA. The binding of 
immune antibodies to the respective immunogens, native and NO-chromatin was 
substantiated by band shift assay. 
(a) Antibodies against native chromatin 
Native chromatin was found to be immunogenic in rabbits. The antiserum 
showed a titre of atieast 1:1600 when tested by direct binding ELISA (Fig. 21). Pre-
immune serum served as negative control, did not show any appreciable binding to 
native chromatin. The specificity of anti-native chromatin antibodies was evaluated 
by competition ELISA. A maximum of 54% inhibition in antibody activity was 
obtained at an immunogen concentration of 20 ng/ml (Fig. 22). Fifty percent 
inhibition was achieved with 18.5 fig/ml of native chromatin. 
(b) Antibodies against NO-chromatin 
NO-chromatin was highly immunogenic in rabbits. The antiserum showed a 
high titre of atieast 1:12800 when tested by direct binding ELISA (Fig. 23). Pre-
immune serum served as negative control, did not show any appreciable binding to 
NO-chromatin. The specificity of anti-NO-chromatin antibodies was evaluated by 
competition ELISA. A maximum of 82% inhibition in antibody activity was obtained 
at 20 |ig/ml. The concentration of immunogen required for 50% inhibition was 
12.19 i^g/ml (Fig. 24). 
Purification and characterization of immune IgG 
Immunoglobulin G was isolated from pre-inimune and immune rabbit sera by 
affinity chromatography on Protein-A Sepharose CL-4B column (Figs. 25, 26). The 
purity of IgG was evaluated by SDS-polyacrylamide gel electrophoresis in the 
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Table 7 
Levels of modification of DNA bases in isolated DNA of 
NO-chromatin 
Base Percent modiflcation of DNA in NO-chromatin 
Adenine 14% 
Guanine 46% 
Cytosine 25% 
Thymine 7% 
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Fig. 21. Direct binding ELISA of native chromatin with preimmune (A) and 
immune sera (A). Microtitre plates were coated with native chromatin 
(2.5 Jig/ml). 
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Fig. 22. Inhibition ELISA of anti-native chromatin immune (o) and pre-immune 
(•) sera with native chromatin. Microtitre plates were coated with native 
chromatin (2.5 |jg/ml). 
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Fig. 23. Direct binding ELISA of NO-chromatin with preimmune (A) and immune 
sera {A.). Microtitre plates were coated with NO-chromatin (2.5 |Jig/ml). 
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Fig. 24. Inhibition ELISA of anti-NO-chromatin immune (o) and preimmune (•) 
sera with NO-chromatin. Microtitre plates were coated with NO-chromatin 
(2.5 Hg/ml). 
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absence of a reducing agent. The purified IgG migrated as a single band upon 
electrophoresis (Figs. 25, 26). 
Direct binding ELISA of the purified IgGs exhibited strong binding to the 
respective immunogens (Figs. 27, 28). Pre-immune IgGs as negative control showed 
negligible binding. The specificity of purified IgG was evaluated by competitive 
inhibition assays. 
Band shift assay 
The binding of native and NO-chromatin to their immune IgG was further 
ascertained by band shift assay. Constant amounts of native and modified chromatin 
were incubated with varying amounts of respective immune and pre-immune IgG for 
2 hr at room temperature and overnight at 4 °C. The immune complex were then 
electrophoresed on 1% agarose for 2 hr at 30 mA. Figure 29 shows the formation of 
immune complexes between native chromatin and anti-native chromatin IgG. With 
increasing concentration of IgG, retardation of the chromatin band was observed with 
the amount of unbound chromatin showed a proportional decrease in intensity. While 
in case of NO-chromatin and anti-NO-chromatin IgG, with increasing concentration 
of IgG, the formation of high molecular weight immune complexes increased as 
judged by their fluorescence intensity in the wells, whereas retardation of chromatin 
bands were observed along with decreased intensity of unbound antigen (Fig. 30). 
While no appreciable change was observed with pre-immune IgG. 
Immuno-crossreactivity of anti-native chromatin antibodies 
The antigenic specificity of the induced native chromatin antibodies was 
characterized by competition inhibition assay. Figures 31 to 35 show the inhibition of 
anti-native chromatin antibody binding to native chromatin using various inhibitors. A 
maximum of 73% inhibition of anti-native chromatin antibody with immunogen as 
inhibitor was observed (Fig 31). Fifty percent inhibition was achieved with only 13.7 
fxg/ml of native chromatin. Figure 32 shows 33% inhibition with NO-chromatin as 
inhibitor for anti-native chromatin IgG. While histone proteins, histone (H2A) and its 
nitric oxide modified form (N0-H2A) as inhibitors showed 19% and 12% inhibition 
at 20 ng/ml inhibitor concentration with anti-native chromatin IgG respectively (Fig. 
33(a), (b)). Figure 33(c) and 33(d) show 22.4% and 11% inhibition with native calf 
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Fig.25 Elution profile of anti-native chromatin IgG on Protein-A Sepharose CL-
4B affinity column. Inset: SDS-PAGE of purified IgG on 7.5% 
polyacrylamide gel with 2.5% stacking gel. 
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Fig. 26. Elution profile of anti-NO-chromatin IgG on Protein-A Sepharose CL-4B 
affinity column. Inset: SDS-PAGE of purified IgG on 7 5% 
polyacrylamide gel with 2.5% stacking gel. 
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Fig. 27. Binding of affinity purified anti-native chromatin immune IgG (A) and 
preimmune IgG (A) to native chromatin. Microtitre plates were coated 
with native chromatin (2.5 fig/ml). 
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Fig. 28. Binding of affinity purified anti-NO-cliromatin immune IgG (A) and 
preimmune IgG (A) to NO-chromatin. Microtitre plates were coated with 
NO-chromatin (2.5 |ig/ml). 
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Fig. 29. Band shift assay of (a) preimmune and (b) immune anti-native chromatin 
IgG binding to native chromatin. Native chromatin (2 \ig) was incubated 
with buffer (lane 1) and 20, 30, 50 and 60 ]xg IgG through lanes 2 to 5, 
respectively for 2 hr at 37 °C and overnight at 4 °C. Electrophoresis was 
carried out on 1% agarose gel for 2 hr at 30 mA. 
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Fig. 30. Band shift assay of (a) preimmune (b) immune anti-NO-chromatin IgG 
binding to NO-chromatin. NO-chromatin (2 |jg) was incubated with buffer 
(lane 1) and 20, 30, 50, and 60 |ag IgG through lanes 2 to 5, respectively 
for 2 hr at 37 °C and overnight at 4 "C. Electrophoresis was carried out on 
1% agarose gel for 2 hr at 30 mA. 
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Fig. 31. Inhibition of anti-native chromatin IgG (•) and anti-NO-chromatin IgG (o) 
binding to native chromatin and NO-chromatin, respectively. The inhibitor 
used was native chromatin. Microtitre plate was coated with respective 
antigens (2.5 |ig/ml). 
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Fig. 32. Inhibition of anti-native chromatin IgG (•) and anti-NO-chromatin IgG (o) 
binding to native chromatin and NO-chromatin, respectively. The inhibitor 
used was NO-chromatin. Microtitre plate was coated with respective 
antigens (2.5 |ig/ml). 
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Fig. 33. Inhibition of anti-native chromatin IgG (•) and anti-NO-chromatin IgG (o) 
binding to native chromatin and NO-chromatin, respectively. The 
inhibitors used were (a) histone (H2A), (b) NO-histone (H2A), (c) native 
calf thymus DNA and (d) ROS-400bp DNA. Microtitre plate was coated 
with respective antigens (2.5 |ig/ml). 
84 
thymus DNA and ROS-400bp DNA as inhibitors used for anti-native chromatin IgG. 
PoIy-L-tyrosine, nitric oxide modified poly-L-tyrosine and peroxynitrite modified 
poly-L-tyrosine gave only 12%, 11% and 14% inhibition at 20 i^g/ml inhibitor 
concentration, respectively (Fig. 34(a), (b) and (c)). Figures 34(d) and 35(a), (b) show 
50%, 21.2% and 25% inhibition with native nucleosome, ROS-nucleosome and NO-
nucleosome as inhibitors used for anti-native chromatin IgG. While human serum 
albumin (HSA) as inhibitor showed 54.2% inhibition with anti-native chromatin IgG 
(Fig. 35(c)). While Figure 35(d) shows 37% inhibition for ROS-HSA as inhibitor with 
anti-native chromatin IgG. 
Immuno-crossreactivity of anti-NO-chromatin antibodies 
The anti-NO-chromatin antibodies exhibited wide range of heterogeneity as 
demonstrated by inhibition assays, using the immunogen, histone and blood proteins, 
proteins polymers, nucleic acid and DNA-protein complex (nucleosomes) as 
inhibitors. Figures 31 to 35 show inhibition studies of anti-NO-chromatin antibodies 
with various inhibitors used. A maximum of 98.4% inhibition in the binding of anti-
NO-chromatin IgG with immunogen as inhibitor was observed (Fig. 32). Fifty percent 
inhibition was achieved at 10.16 |^ g/ml of NO-chromatin. Native chromatin as 
inhibitor showed an inhibition of around 35% at 20 jig/ml of inhibitor concentration 
with anti-NO-chromatin IgG (Fig. 31). Figure 33(a) and (b) show moderate inhibition 
of 33.2% and 48% with histone (H2A) and N0-H2A as inhibitors used for anti-NO-
chromatin IgG. Native calf thymus DNA and ROS-400bp DNA showed only 14.3% 
and 19% inhibition with anti-NO chromatin IgG (Fig. 33(c), (d)). While poly-L-
tyrosine, nitric oxide modified poly-L-tyrosine and peroxynitrite modified poly-L-
tyrosine as inhibitors gave 20%, 38% and 46% inhibition, respectively (Fig. 34(a), (b) 
and (c)). Native nucleosome, ROS-nucleosome and NO-nucleosome as inhibitors 
showed moderate to high inhibition of 37%, 35.3% and 70% with anti-NO-chromatin 
IgG respectively (Figs. 34(d) and 35(a), (b)). 50% inhibition for NO-nucleosome was 
achieved at 14.2 |ag/ml of inhibitor concentration. While human serum albumin 
(HSA) and ROS-HSA were found to be potent inhibitors, showing maximum 
inhibition of 64% and 63% with anti-NO-chromatin antibodies, respectively (Fig. 
35(c) and (d)). 50% inhibition with HSA and ROS-HSA was achieved at 15.6 ng/ml 
and 15.8 i^g/ml of inhibitor concentration respectively. 
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Fig. 34. Inhibition of anti-native chromatin IgG (•) and anti-NO-chromatin IgG (o) 
binding to native chromatin and NO-chromatin, respectively. The 
inhibitors used were (a) poiy-L-tyrosine, (b) NO-poly-L-tyrosine, (c) 
ONOO"-poly-L-tyrosine and (d) native nucleosome. Microtitre plate was 
coated with respective antigens (2.5 fig/ml). 
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Fig. 35. Inliibition of anti-native chromatin IgG (•) and anti-NO-chromatin IgG (o) 
binding to native chromatin and NO-chromatin, respectively. The 
inhibitors used were (a) ROS-nucleosome, (b) NO-nuclcosome (c) human 
serum albumin (HSA) and (d) ROS-HSA Microtitre plate was coated with 
respective antigens (2.5 ^ ig/ml). 
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Table 8 summarize the results of the inhibition studies of anti-native 
chromatin and anti-NO-chromatin antibodies with various inhibitors. 
Quantitation of anti-DNA antibodies in SLE sera 
Various SLE serum samples were tested for the presence of anti-DNA 
antibodies by direct binding ELISA. Out of the 28 serum samples tested, those (10 
sera) showing high titre ranging form 1:1600 to 1:6400 of anti-DNA antibody binding 
are depicted in Figures 36-38. The samples were subsequently employed for their 
binding to native chromatin and NO-chromatin. Normal human sera showed 
negligible binding with either of the antigens. 
Purification of SLE IgG 
Protein A binds IgG from most mammalian species through interactions with 
the Fc part of IgG molecules (Langone, 1978). SLE IgGs from 10 sera were purified 
by affinity chromatography on Protein-A Sepharose CL-4B column. The purified 
IgGs from normal and SLE sera were found to be eluted in a single symmetrical peak 
(Fig. 39). The homogeneity of the IgG was checked by SDS-PAGE under non-
denaturing condition and was found to migrate as a single band. 
The binding of one of the purified IgGs with native and NO-chromatin was 
studied by direct binding ELISA. High magnitude of binding was observed with NO-
chromatin as compared to native chromatin (Fig. 40). With normal human serum no 
appreciable binding was observed. The binding specificity was further ascertained by 
inhibition ELISA. 
Immuno-crossreactivity of anti-DNA autoantibodies 
The binding pattern of SLE anti-DNA autoantibodies to native calf thymus 
DNA, native chromatin and nitric oxide modified chromatin was determined by direct 
binding ELISA. All the ten sera showed appreciable binding to native and NO-
chromatin. Preferentially high binding was observed in case of NO-chromatin. 
Figure 41 shows the enhanced binding of SLE anti-DNA autoantibodies (1:100 
diluted) with NO-chromatin as compared to native chromatin and native calf thymus 
DNA. Normal human serum showed no appreciable binding. 
The antigen binding specificity of isolated SLE IgGs was tested with all the 
three antigens i,e native calf thymus DNA, native chromatin and NO-chromatin as 
inhibitors by competition inhibition ELISA. The microtitre plates were coated with 
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Table 8 
Antigenic binding characteristics of anti-native chromatin and 
NO-chromatin antibodies 
I hih'tor Maximum%inhibition at 20 |xg/ml 
Native chromatin NO-chromatin 
Native chromatin 73 34.7 
NO-chromatin 
Histone (H2A) 
NO-histone (H2A) 
Native calf thymus DNA 
ROS- 400bp DNA 
Poly-L-tyrosine 
NO-poly-L-tyrosine 
ONOO-poly-L-tyrosine 
Native nucleosome 
ROS-nucleosome 
NO-nucleosome 
Human serum albumin (HSA) 
ROS-HSA 
33 
19 
12 
22.4 
11 
12 
11 
14 
50 
21.2 
25 
54.2 
37 
98.4 
33.2 
48 
14.3 
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20 
38 
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35.3 
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Fig. 36. Evaluation of anti-DNA autoantibodies in SLE patients. The microtitre 
plates were coated with native calf thymus DNA (2.5 pg/ml). Curves (•), 
(v), (y), (o) and (•) represent SLE sera 1, 2, 3, 4 and normal human serum 
pool respectively. 
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Fig. 37. Evaluation of anti-DNA autoantibodies in SLE patients. The microtitre 
plates were coated with native calf thymus DNA (2.5 pig/ml). Curves (o), 
(K7), (•) and (•) represent SLE sera 5, 6, 7 and normal human serum pool 
resF>ectiveIy. 
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Fig. 38. Evaluation of anti-DNA autoantibodies in SLE patients. The microtitre 
plates were coated with native calf thymus DNA (2.5 ng/ml). Curves (v), 
('''). i^) and (•) represent SLE sera 8, 9, 10 and normal human serum pool 
respectively. 
92 
0.75 -
0.50-
0-25 -
E 
c 
§ 0.00 
o 
I 0.75 
o 
to 
XI 
< 
0.50 -
0.2 5 -
0.00 
Fraction Number 
Fig. 39. ^'"t^on Profile of (a) Normal human IgG (b) IgG f-^or. an SLE patient on 
Protem-A Sepharose CL-4B column. Inset: SDS-PAGE of purified IgG on 
7.5% poly aery lamide gel with 2.5% stacking gel. 
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Fig. 40. Binding of affinity purified SLE IgG to native (o) and NO-chromatin (T). 
Normal human IgG (•) to either of the antigens coated on plates 
(2.5^ig/ml). 
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Fig 41 Direct binding ELISA of human SLE anti-DNA autoantibodies to native 
calf thymus DNA ( | 0 , native chromatin ( ^ ^ ) ^"^ NO-chromatin (fllll)-
Microtitre plates were coated with 2.5 i^g/ml of respective antigens. 
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native calf thymus DNA (2.5 |ag/ml). A single SLE IgG was incubated with all the 
three antigens i,e native calf thymus DNA, native chromatin and NO-chromatin and 
then assayed for residual binding with native calf thymus DNA coated plates. Native 
calf thymus DNA as inhibitor showed 35% to 60% inhibition in ten SLE samples 
(Figs. 42-51). 
Native chromatin showed inhibition ranging form 45% to 60% with ten SLE 
IgG tested for binding with native calf thymus DNA. NO-chromatin showed relatively 
high percent inhibition with ten SLE IgG tested for binding with native calf thymus 
DNA. One of the SLE IgG showed inhibition to an extent of 73% while the binding of 
two SLE IgGs was inhibited to an extent of 58% and 56% respectively. 
Table 9 shows the inhibition result for all the three antigens i,e native calf 
thymus DNA, native and NO-modified chromatin indicating the mean value and 
standard deviation. Student (t) test performed for native and NO-chromatin gave 
t = 4.6 with p<0.001. While no significant difference in binding to nCT DNA and 
native chromatin was seen. 
Band shift assay 
Band shift assay was employed to visualize and thus confirm the interaction of 
native and NO-chromatin with SLE autoantibodies. A constant amount of the antigen 
was incubated with increasing amovints (0-80 ^g) of SLE IgG for 2 hr at 37 °C and 
overnight at 4 °C. The immune complexes were then electrophoresed on 1% agarose 
for 2 hr at 30 mA. Figure 52 show the binding of anti-DNA autoantibodies to native 
and NO-modified chromatin. With increasing concentration of IgG, there is a 
corresponding increase in the formation of high molecular weight immune complexes 
which resulted in retarded mobility and corresponding decrease in the fluorescence 
intensity of unbound antigen. Normal human IgG incubated under identical condition 
did not show immune complex formation. 
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Fig. 42. ^ibition of SLE serum 1 autoantibody binding with native calf thymus 
DNA (•) native chromatin (o) and NO-chromatin (T). Microtitre plates 
were coated with native calf thymus DNA (2.5 ftg/ml). 
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Pig 43 Inhibition of SLE serum 2 autoantibody binding with native calf thymus 
DNA (•) native chromatin (o) and NO-chromatin (T). Microtitre plates 
were coated with native calf thymus DNA (2.5 ^g/ml). 
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Fig. 44. Inhibition of SLE serum 3 autoantibody binding with native calf thymus 
DNA (•) native chromatin (o) and NO-chromatin ( • ) . Microtitre plates 
were coated with native calf thymus DNA (2.5 |ig/m!). 
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Fig, 45 Inhibition of SLE serum 4 autoantibody binding with native calf thymus 
DNA (•) native chromatin (o) and NO-chromatin (T). Microtitrc plates 
were coated with native calf thymus DNA (2.5 ^ g/ml). 
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Fig. 46. Inliibition of SLE serum 5 autoantibody binding witli native calf thymus 
DNA (•) native chromatin (o) and NO-chromatin (T). Microtilre plates 
were coated with native calf thymus DNA (2.5 ug/ml). 
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Fig. 47. Inhibition of SLE serum 6 autoantibody binding with native calf thymus 
DNA (•) native chromatin (o) and NO-chromatin (T). Microtitre plates 
were coated with native calf thymus DNA (2.5 ^g/ml). 
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Fig. 48. Inhibition of SLE serum 7 autoantibody binding with native calf thymus 
DNA (•) native chromatin (o) and NO-chromatin ( T ) . Microtitre plates 
were coated with native calf thymus DNA (2.5 fig/ml). 
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Fig. 49. Inhibition of SLE serum 8 autoantibody binding with native calf thymus 
DNA (•) native chromatin (o) and NO-chromatin (T). Microtitre plates 
were coated with native calf thymus DNA (2.5 fag/ml). 
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Fig. 50. Inhibition of SLE serum 9 autoantibody binding with native calf thymus 
DNA (•) native chromatin (o) and NO-chromatin (T). Microtitre plates 
were coated with native calf thymus DNA (2.5 fig/ml). 
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Fig. 51. 
r^r'l' ,'°? ^^^ '^"™ ^° autoantibody, binding with native calf thymus 
DNA (.) native chromatin (o) and NO-chromatin (T). Microtitre plates 
were coated with native calf thymus DNA (2.5 ^g/ml) 
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Table 9 
Inhibition of SLE autoantibodies binding to native calf thymus DNA 
by native calf thymus DNA, native chromatin and NO-chromatin 
SLE IgG 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
Mean±SD 
Maximum Percent Inhibition At 20 fxg/ml 
nCT DNA 
54 
42 
40 
56 
55 
60 
55 
50 
35 
48 
49.5±7.8 
Native Chromatin 
55 
46 
47 
60 
58 
45 
59 
53 
50 
45 
51.9±6.1 
NO-chromatin 
63 
58 
32 
70 
65 
58 
73 
63 
60 
56 
62.8+5.3 
Microtitre plates were coated with nCT DNA (2.5 i^ g/ml) 
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Fig. 52. Band shift assay of SLE IgG binding to (a) native chromatin and (b) NO-
chromatin. Antigen (2 }ig) was incubated with buffer (lane 1) and 20,40,60 
and 80 \xg of IgG through lane 2 to 5j respectively in (a) while 20, 60 and 
80 mg of SLE IgG through lane 2 to 4 in (b). The immune complex was 
incubated for 2 hr at 37 °C and overnight at 4 °C. Electrophoresis was 
performed on 1% agarose gel for 2 hr at 30 mA. 
2) L6CVl66LOn. 
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Human are exposed to a wide range of nitrogen-containing compounds and 
nitrosating agents, such as nitrite, nitrate and nitrogen oxides, that can react in vivo to 
form potentially carcinogenic N-nitroso compounds as well as several carcinogenic 
C-nitro or reactive diazo compounds. Nitrosating agents can also be synthesized 
endogenously by bacteria and activated macrophages via the nitric oxide synthase 
(NOS) pathway. Endogenous nitrosation can thus occur at many locations in the body, 
including sites of chronic inflammation or infection (Bartsch and Frank, 1996; Felley-
Bosco, 1998). Nitric oxide a multifaceted bioregulatory agent, shows an unusual 
divergence of action. It is demonstrated to play a major role as neurotransmitter and a 
regulator of blood pressure. Macrophages also use nitric oxide as a cytotoxic agent 
which may lead to DNA damage. The effects of nitric oxide at the DNA level are 
complex and involve formation of N-nitrosoamines, deamination of purines and 
pyrimidines, or damage induced by peroxynitrite. Besides inducing DNA damage, 
nitric oxide may also inactivate DNA repair/replication enzymes (Delaney and 
Eizirik, 1996; Luperchioe/a/., 1996). 
In addition to the broad repertoire of regulatory functions, nitric oxide serves 
in mammalian physiology, the L-arginine: NO pathway is also involved in numerous 
patho-physiological mechanisms. The role of nitric oxide in numerous disease states 
has generated considerable discussion over the past several years. Nitric oxide 
mediated cell injury may arise by a variety of mechanisms, including disruption of 
mitochondrial respiration, enzymes inhibition, lipid peroxidation and genetic 
mutation. Toxicity is largely mediated via intermediates such as N2O3 and 
peroxynitrite, arising from the reaction of nitric oxide with either molecular oxygen or 
reactive oxygen species. In general, such reactions become significant only when high 
concentrations of nitric oxide are generated by the induction of NOS (Gordge, 1998; 
Wink et al., 1998a and b). Nitric oxide is an important mediator of the inflammatory 
response. Over expression of N0S2 and overproduction of nitric oxide are parallel 
with the development of an autoimmune syndrome with a variety of inflammatory 
manifestations (Gilkeson et al., 1997). Nitric oxide is involved in a number of 
immunopathologies, including diabetes, graft-vs-host reaction, rheumatoid arthritis, 
SLE and multiple sclerosis (Cook and Cattell, 1996; Parkinson et al., 1997; Kuhn et 
al., 1998). 
Nitric oxide is a paramagnetic diatomic, uncharged molecule with an unpaired 
electron. These characteristics make it highly reactive, having a half life of 2 to 30 
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seconds (Halliwell and Gutteridge, 1989; Lowenstein et al.,1994). Saturated solutions 
of nitric oxide have been demonstrated to deaminate deoxyribonucleosides, 
deoxyribonucleotides and intact DNA under aerobic conditions in vitro (Keefer et al., 
1991). Nitric oxide and its progenitors have been shown to be mutagenic to Samonella 
typhimurium (Keefer et al, 1991; Arroyo et al, 1992), rat lung cells foUov^ng in 
vivo exposure (Isomura et al, 1984) and human TK6 lymphoblastoid cells in culture 
(Nguyen et al, 1992). Purines are more readily deaminated than pyrimidines. 
However, some unexpected bases like 8-hydroxyadenine and 8-hydroxyguanine are 
also found (Lin et al, 1993a). The GC—> AT transitions predominate in molecular 
mechanisms of mutagenesis in cells exposed to nitric oxide. Nitric oxide damages 
DNA by diazotisation of primary arylamines in an oxidizing envirorunent (Ji and 
Bellocher, 1988; Rait et al, 1988; Kosaka et al, 1989). Xanthine and hypoxanthine 
from deamination of guanine and adenine respectively leads to mispairing (Duncan 
and Miller, 1980; Eritja et al, 1986), and the instability of hypoxanthine and xanthine 
in DNA leads to depurination and subsequent strand breakage (Lindahl and Anderson, 
1972). Both of these phenomenon have been observed in calf thymus DNA and in 
intact cells and potentially contribute to both cytotoxicity and mutagenicity (Loeb and 
Preston, 1986; Nguyen et al, 1992). A third possibility is the formation of intrastrand 
crosslinks via attack of the aryl diazonium ion of one purine on the free amino group 
of a second purine in the matching strand (Singer and Grunberger, 1983; Kirchner and 
Hopkins, 1991). 
There is an evidence for a pathological role of nitric oxide in inflammatory 
diseases (Bagasra et al, 1995; Buttery et al, 1996; Parkinson et al, 1997; van deer 
Veen et al, 1997). Lowenstein et al (1994) postulated that DNA damage by nitric 
oxide may affect the development of autoimmune diseases. Subsequent release of 
altered DNA during apoptosis may enable it to act as an antigen inducing antibodies 
crossreacting with nDNA (Herrmann et al, 1996; Casciola-Rosen and Rosen, 1997). 
Apoptosis is an important mechanism of cell destruction by nitric oxide (Burkart et 
al, 1994; Zcttl et al, 1997). Exposure to endogenously and exogenously produced 
nitric oxide is extensive, and in the presence of oxygen, nitric oxide can cause a 
variety of damages to DNA as well as mutations in various cell lines in culture. For 
example, Chinese hamster ovary (CH0-AA8) and human lymphoblastoid (TK6) cell 
lines when treated with nitric oxide showed apoptosis along with the occurrence of 
DNA strand breaks, inhibition of DNA synthesis, damage to mitochondria, changes in 
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cell cycle and loss of cell membrane integrity (Bumey et al., 1997). Therefore, the 
cytotoxicity and mutagenicity associated with the inflammatory process may result 
from nitric oxide radicals in addition to the better known reactions of oxygen radicals. 
SLE is a systemic autoimmune disorder characterized by a marked diversity of 
organ involvement and fluctuations in disease activity (Min et al., 2002). Although 
the pathogenesis process of SLE has not yet been clearly established, several 
autoantibodies have been implicated in its pathogenesis and in tissue damage (Koffler, 
1974; Tan et al., 1988). Antibodies to DNA in SLE have been extensively studied and 
may be specific for ssDNA, reactive vath both ssDNA and dsDNA, or specific for 
dsDNA (StoUar, 1979; Worral et al, 1990). Anti-dsDNA antibodies are strongly co-
related with diagnosis of SLE (Tan, 1989) Serum antibodies reacting with chromatin 
or its predominant components, histones and DNA, have been found in SLE, drug 
induced lupus, several other human disease states and in murine models of SLE 
(Schwartz and Stollar, 1985; Burlingame and Rubin, 1991; Theofilopoulos and 
Dixon, 1985; Portanova et al, 1988; Costa and Monier, 1986; Fisher et al, 1988). 
Chromatin is an immunogenic stimulus for B cells in SLE and anti-native DNA 
antibodies are a subset of the wide range of anti-chromatin antibodies produced in this 
disease (Burlingame et al, 1994). It has been reported that immunization of BALB/c 
mice with active chromatin isolated from Con A-activated syngeneic spleno-
lymphocytes induce SLE-like syndrome in mice (Li et al, 2004). Further, the loss of 
tolerance to chromatin mediated by Sle 1 gene loci is essential for disease 
pathogenesis and resulted in severe systemic autoimmunity in a polycongenic murine 
strain (Morel et al, 2000). 
It has been suggested that under certain circumstances, there is an accelerated 
apoptosis of circulating lymphocytes in SLE patients. This increased rate of apoptosis 
could lead to an overflow of the apoptotic cell material and thus increased nuclear 
components both normal and modified e.g. dsDNA, nucleosomes or histone in serum 
of these patients which could be presented to and recognized as nonself antigens by 
immunocompetent cells, leading to the formation of autoantibodies (Gabler et 
a/.,2003; Ahsan et al, 2003). In addition dysregulated apoptosis and/or phagocytosis 
may trigger and provide survival signals for autoreactive B cells (Lorenz et al, 2000; 
Berden et al, 1999). Also, nucleosomes have been shown to be exposed at the cell 
surface in apoptosis leading to autoantibodies generation. (Radic et al, 2004). Thus 
for these reasons, it was thought desirable to investigate the damage induced by nitric 
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oxide on chromatin isolated from goat liver and study its inmiunogenicity and 
possible role in SLE. 
In the present study chromatin was isolated from goat liver tissue which 
exhibited major peak at 260 nm and migrated as a single homogenous electrophoretic 
band on 1% agarose gel. 
Isolated chromatin was modified by nitric oxide radicals (NO), generated by 
the reduction of sodium nitrite with sodium dithionite. The production of nitric oxide 
was confirmed by the use of specific quencher, carboxy PTIO (Maeda et ai, 1994). 
'Nearly complete inhibition of the nitric oxide production was observed in the 
presence of 110 mM carboxy PTIO. While the inhibition was decreased with 
decreasing concentration of carboxy PTIO, confirming the damage caused by nitric 
oxide. 
UV absorption spectra of NO-chromatin showed loss of peak and 
hyperchromicity at 260 nm as compared to its native form. This could be attributed to 
strand breaks and modification of bases in DNA of chromatin. The UV difference 
spectral curve exhibited increased absorbance around 240 nm. This is indicative of an 
appreciable proportion of nitric oxide induced damage of bases and disruption of 
chromatin structural organization. 
Fluorescence studies of NO-chromatin compared with native chromatin 
showed prominent changes in spectral studies. At 260 nm excitation wavelength used, 
there was decrease in fluorescence intensity which could be attributed due to single 
strand generation and alterations in structural organization incurred by nitric oxide. 
While at 280 nm excitation wavelength, the emission spectra showed marked increase 
of fluorescence intensity which could be explained in terms of protein chromophoric 
group exposure due to alteration in the structure of chromatin by nitric oxide. 
The thermal denaturation profile of native and NO-chromatin at 260 nm 
showed a net decrease of 9 °C in the Tm value for the modified chromatin compared 
to it unmodified form. The lowered Tm of NO-chromatin could be attributed to the 
disruption of hydrogen bonding pattern, generation of single stranded regions or due 
to structural alterations of chromatin. While thermal denaturation profile of native and 
NO-chromatin taken at 280 nm showed stability of modified sample as compared to 
its native form. Tm value for NO-chromatin was found to be higher than for its 
unmodified form. This stability of modified sample can be attributed to protein-
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protein/protein-DNA cross linking/adduct formation occurring as a result of structural 
modifications incurred by nitric oxide. 
Formation of single stranded regions in modified chromatin was confirmed by 
nuclease SI digestibility of native and modified chromatin. A substantial decreased 
intensity in case of modified sample was found. However, the intensity loss in case of 
native chromatin shows that some of the single stranded regions are present in 
unmodified sample also, but intensity loss was more in case of modified sample 
showing the formation of single stranded region on exposure to NO. The data is 
compatible with earlier reports indicating nitric oxide radicals resuU in strand 
breakage (Kolb et al., 1993; Sugiura and Matsumoto, 1995). 
The CD spectra was taken at wavelength range 200 nm-250 nm, where native 
chromatin showed two negative peaks at 208 nm and 223 nm, while NO-chromatin 
compared to native chromatin showed a red shift fi-om 208 nm to 217 nm, retained its 
223 nm peak and appearance of shoulder at 230 nm, with decreased ellipticity. 
While in wavelength range 250 nm-300 nm, native chromatin showed positive band 
while NO-chromatin retained the positive band with decreased ellipticity as well. This 
study indicates the loss of protein and DNA due to damage caused by nitric oxide 
along with changes in protein/peptide and/or protein-DNA organization and base 
modification/formation of strand breaks in DNA. NO is known to cause DNA damage 
through DNA intrastrand, DNA interstrand, DNA strand breakage and DNA-protein 
cross link formation via the N2O3 intermediate (Bumey et al., 1997). 
Nitric oxide was also found to produce base modifications in DNA extracted 
from NO-chromatin. Guanine was modified maximally followed by cytosine. These 
results are consistent with earlier studies which demonstrate greater susceptibility of 
guanine and cytosine to modification by nitric oxide (Sugiura and Matsumoto, 1995; 
Caulfield etal., 1998; Grishko etai, 1999). 
Native DNA per se is known to be a poor immunogen (Madio et al., 1984; 
Stollar, 1986), whereas some synthetic homopolynucleotides, chemically modified 
DNA, helical synthetic polynucleotides and denatured DNA are immunogenic while 
RNA-DNA hybrid, left handed Z-DNA, triple helical RNA and DNA analogues, 
double helical polydeoxyribonucleotides, DNA modified with drugs, hormones, 
chromatin or DNA in complexes with DNA binding proteins as well (Stoller, 1973; 
1975; 1986; Anderson et al., 1988a; Desai et al., 1993; Moinuddin and Ali, 1994; 
Hasan et al., 1995; Theofilopoulos 1995; Arif and Ali, 1996; Arjumand et al, 1995; 
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1997). Reactive oxygen species modified DNA have been implicated in the 
pathogenesis of SLE (Ara and Ali, 1992; 1993; 1995; Ahmad et al., 1997; Cooke et 
al., 1997). Attempts to immunize non-autoimmune mice with nucleosomes prepared 
in vitro have failed, giving support to the notion that qualitative modifications of 
nucleosomes are necessary for autoantibody induction (Amoura et al., 1999). 
Chromatin itself is immunogenic. But in diseases like SLE it becomes more 
immunogenic (Hardin, 1986; Chabre et al., 1995; Mohan et al., 1993; Burlingame et 
al., 1993; 1994). This might be due to the exposure of chromatin to various free 
radicals including nitric oxide radicals altering the structure of chromatin and 
rendering it more immunogenic. It has been suggested previously that the change of 
chromatin's antigenicity by environmental factors and genetic background may be the 
common pathway to SLE pathogenesis (Lu et al., 1998). 
Both native and modified chromatin was found to be immunogenic in rabbits 
as revealed by direct binding and inhibition ELISA results. But NO-chromatin was 
found to be highly immunogenic as compared to unmodified native chromatin. Band 
shift assays clearly demonstrated the absolute specificity of the purified immune IgG 
towards their respective immunogen. Antigenic specificity of purified IgG was 
confirmed by inhibition ELISA. A maximum of 73% inhibition of anti-native 
chromatin antibody with immunogen as inhibitor was observed at 20 i^g/ml and 50% 
inhibition was achieved at 13.7 |ig/ml. A maximum of 98% inhibition in the binding 
of anti-NO-chromatin antibody with immunogen as an inhibitor at 20 fig/ml was 
observed and 10.2 |jg/ml of immunogen was required for 50% inhibition. The data 
shows that although native chromatin was found to be immunogenic in experimental 
animals but chromatin modified with nitric oxide was found to be highly 
immunogenic. This could be correlated to a feature of SLE wherein nitric oxide 
modified chromatin may play major role in the production of SLE autoantibodies by 
the modification of DNA (or nucleosomes) thus forming neoantigens(s) resulting in 
the production of autoantibodies (Dixit and Ali, 2004). 
Antibodies raised against native and NO-chromatin were further determined 
for their antigenic binding characteristics with various inhibitors like tyrosine 
polymer, blood proteins, histone protein, DNA and modified form of nucleosome. 
Besides showing strong recognition for their respective immunogen, histone (H2A), a 
core binding protein in nucleosome, showed negligible inhibition with native 
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chromatin as compared to NO-chromatin whereas nitric oxide modified H2A showed 
moderate inhibition with NO-chromatin as compared to native chromatin. It is 
reported that the antigenicity of the histones present in chromatin is markedly 
diminished as compared to the antigenicity of the histones free in solution (Goldblatt 
et ai, 1980). However histones on modification with nitric oxide generate similar 
epitopes as recognized by anti-NO-chromatin antibodies. While pure dsDNA or ROS 
modified DNA fragment (ROS-400bp) did not appreciably recognized the induced 
antibodies. It may be concluded that DNA alone may not be responsible for antibody 
generation rather DNA-protein complex is the neoepitope recognized by antibodies 
against native and NO-chromatin. It has been reported that SLE sera often bound to 
several different epitopes on chromatin with some epitopes requiring quaternary 
protein-DNA interactions. (Burlingame et al., 1994). Also native nucleosome, ROS-
nucleosome and NO-nucleosome show moderate to high percent cross-reactivity for 
antibodies generated against native and NO-chromatin. 3-Nitrotyrosine is a biological 
marker of oxidative damage by nitric oxide (Ischiropoulos et al., 1992; Beckman et 
ai, 1990). Native tyrosine polymer was used as inhibitor and it showed negligible 
inhibition as compared to tyrosine polymer modified with nitric oxide and one of its 
radical, peroxynitrite. Thus it shows that tyrosine on nitration generate epitope for 
antibody recognition similar to epitopes recognized by anti-native and anti-NO-
chromatin antibodies. While blood protein like human serum albumin and its ROS 
modified form showed moderate to high recognition for antibodies, indicating similar 
epitope recognition by antibodies generated against native and NO-chromatin. Thus 
analysis of the data indicate that anti-NO-chromatin IgG is polyspecific and the 
various cross-reacting inhibitors with which it reacts, share a common antigenic 
determinant or epitope. 
Several studies have reinforced the concept that SLE is an anti-chromatin 
disease i.e. the autoimmune response is against chromatin with the development of 
antibodies directed to various epitopes on chromatin including but not limited to DNA 
(Burlingame et al., 1993; Tax et al., 1995; Chabre et al., 1995). There is an evidence 
for a pathological role of nitric oxide in inflammatory diseases (Bagasra et al., 1995 
Buttery et al., 1996; Parkinson et al., 1997; van deer Veen et al., 1997). Further, 
evidence of the role of nitric oxide in SLE is provided by various studies (Belmont et 
al., 1997; Gilkeson et al., 1997; Wigand et al., 1997). Plasma nitrite concentrations 
were also found to be significantly higher in SLE patients as compared with control 
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subjects. (Ho et al, 2003; Wong et al, 2002). Apoptosis is an important mechanism 
of cell destruction by nitric oxide (Burkart et al, 1994; Zettl et al, 1997). Also, 
nuclesome core particles have been implicated in the induction of circulating human 
autoantibodies in systemic autoimmunity (Gabler et al, 2003). 
In the present study, the possible involvement of NO-chromatin and native 
chromatin in SLE was probed. A number of SLE sera were used to study the possible 
role of NO-induced damage to chromatin in anti-DNA autoantibodies production. 
Antibodies to dsDNA serve as an immunochemical marker for the diagnosis of SLE 
(Tan, 1989). Thus, high titre anti-DNA autoantibodies SLE sera were collected. The 
binding specificity of IgGs was investigated by inhibition ELISA using native 
chromatin, NO-chromatin and native calf thymus DNA as inhibitors. The microtitre 
plates were coated with calf thymus DNA. The average percent inhibition (± SD) of 
10 purified SLE IgG binding to native calf thymus DNA, native chromatin,NO-
chromatin was 49.4 ± 7.8, 51.9 ± 6.1 and 62.8 ± 5.3, respectively (Table 9). On 
comparing, the inhibition values of native chromatin and NO-chromatin, a p-value of 
<0.001 indicated significant difference in the binding of these two antigens. While no 
significant changes in the recognition of native chromatin and native DNA by SLE 
anti-DNA antibodies was observed. These results indicate that the modified chromatin 
is an effective inhibitor, showing substantial difference in the recognition of NO-
chromatin over native chromatin. Band shift assay further substantiated the binding of 
native and NO-chromatin with SLE anti-DNA autoantibodies. Based on the above 
studies, the following conclusions can be drawn: 
1. Nitric oxide modification of chromatin resulted in the formation of single 
strand breaks and base modifications in DNA of chromatin while protein-
protein cross-linking/protein-DNA adducts were formed disrupting the tertiary 
structure of chromatin. 
2. Fluorescence studies, thermal denaturation profile, CD spectra and nuclease 
SI studies confirmed structural alterations occurring due to nitric oxide 
modification of chromatin. 
3. NO-chromatin was highly immunogenic in experimental animals as compared 
to native chromatin. 
4. Induced antibodies were highly specific for respective immunogen. 
5. The induced antibodies showed polyspecificity, sharing epitopes which 
required quaternary protein -DNA interactions like found in nucleosomes. 
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6. Anti-NO-chromatin IgG recognized human blood proteins, modified tyrosine 
polymer and histones. Moreover, NO-modified conformers were better 
recognized than their native forms. 
7. SLE autoantibodies showed preferential binding to NO-chromatin over native 
chromatin and native calf thymus DNA. 
8. NO-chromatin presents discriminating antigen for the binding of SLE 
autoantibodies. It is suggested that nitric oxide modified chromatin might be 
challenging the immune system, leading to autoantibody production, which 
are polyspecific in nature comparable in binding characteristics to circulating 
autoantibodies in SLE. 
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